US20040121309A1 - Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues - Google Patents
Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues Download PDFInfo
- Publication number
- US20040121309A1 US20040121309A1 US10/323,233 US32323302A US2004121309A1 US 20040121309 A1 US20040121309 A1 US 20040121309A1 US 32323302 A US32323302 A US 32323302A US 2004121309 A1 US2004121309 A1 US 2004121309A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- bioagent
- base
- mass
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Definitions
- the present invention relates to methods for rapid detection and identification of bioagents from environmental, clinical or other samples.
- the methods provide for detection and characterization of a unique mass or unique base composition signature (BCS) from any bioagent, including bacteria and viruses.
- BCS base composition signature
- the unique mass or unique BCS is used to rapidly identify the bioagent(s).
- PCR polymerase chain reaction
- detection and data analysis convert the hybridization event into an analytical result.
- Mass spectrometry provides detailed information about the molecules being analyzed, including high mass accuracy. It is also a process that can be easily automated.
- high-resolution MS alone fails to perform against unknown or bioengineered agents, or in environments where there is a high background level of bioagents (“cluttered” background).
- Low-resolution MS can fail to detect some known agents, if their spectral lines are sufficiently weak or sufficiently close to those from other living organisms in the sample.
- DNA chips with specific probes can only determine the presence or absence of specifically anticipated organisms. Because there are hundreds of thousands of species of benign bacteria, some very similar in sequence to threat organisms, even arrays with 10,000 probes lack the breadth needed to detect a particular organism.
- Antibodies face more severe diversity limitations than arrays. If antibodies are designed against highly conserved targets to increase diversity, the false alarm problem will dominate, again because threat organisms are very similar to benign ones. Antibodies are only capable of detecting known agents in relatively uncluttered environments.
- Electrospray ionization-Fourier transform-ion cyclotron resistance (ESI-FT-ICR) MS may be used to determine the mass of double-stranded, 500 base-pair PCR products via the average molecular mass (Hurst et al., Rapid Commun. Mass Spec . 10:377-382, 1996).
- MALDI-TOF matrix-assisted laser desorption ionization-time of flight
- U.S. Pat. No. 5,849,492 describes a method for retrieval of phylogenetically informative DNA sequences that comprise searching for a highly divergent segment of genomic DNA surrounded by two highly conserved segments, designing the universal primers for PCR amplification of the highly divergent region, amplifying the genomic DNA by PCR technique using universal primers, and then sequencing the gene to determine the identity of the organism.
- U.S. Pat. No. 5,965,363 discloses methods for screening nucleic acids for polymorphisms by analyzing amplified target nucleic acids using mass spectrometric techniques and to procedures for improving mass resolution and mass accuracy of these methods.
- WO 99/14375 describes methods, PCR primers and kits for use in analyzing preselected DNA tandem nucleotide repeat alleles by mass spectrometry.
- WO 98/12355 discloses methods of determining the mass of a target nucleic acid by mass spectrometric analysis, by cleaving the target nucleic acid to reduce its length, making the target single-stranded and using MS to determine the mass of the single-stranded shortened target. Also disclosed are methods of preparing a double-stranded target nucleic acid for MS analysis comprising amplification of the target nucleic acid, binding one of the strands to a solid support, releasing the second strand and then releasing the first strand, which is then analyzed by MS. Kits for target nucleic acid preparation are also provided.
- PCT WO97/33000 discloses methods for detecting mutations in a target nucleic acid by nonrandomly fragmenting the target into a set of single-stranded nonrandom length fragments and determining their masses by MS.
- U.S. Pat. No. 5,605,798 describes a fast and highly accurate mass spectrometer-based process for detecting the presence of a particular nucleic acid in a biological sample for diagnostic purposes.
- WO 98/21066 describes processes for determining the sequence of a particular target nucleic acid by mass spectrometry.
- Processes for detecting a target nucleic acid present in a biological sample by PCR amplification and mass spectrometry detection are disclosed, as are methods for detecting a target nucleic acid in a sample by amplifying the target with primers that contain restriction sites and tags, extending and cleaving the amplified nucleic acid, and detecting the presence of extended product, wherein the presence of a DNA fragment of a mass different from wild-type is indicative of a mutation.
- Methods of sequencing a nucleic acid via mass spectrometry methods are also described.
- WO 97/37041, WO 99/31278 and U.S. Pat. No. 5,547,835 describe methods of sequencing nucleic acids using mass spectrometry.
- U.S. Pat. Nos. 5,622,824, 5,872,003 and 5,691,141 describe methods, systems and kits for exonuclease-mediated mass spectrometric sequencing.
- One embodiment of the present invention is a method of identifying an unknown bioagent in an animal sample comprising a) contacting nucleic acid from the bioagent in the animal sample with at least one pair of oligonucleotide primers that hybridize to sequences of the nucleic acid and flank a variable nucleic acid sequence; b) amplifying the variable nucleic acid sequence to produce an amplification product; c) determining the molecular mass of the amplification product; and d) comparing the molecular mass to one or more molecular masses of amplification products obtained by performing steps a)-c) on a plurality of known organisms, wherein a match identifies the unknown bioagent in the animal sample.
- Animal samples include blood, bodily fluid and bodily tissue.
- the sequences to which the at least one pair of oligonucleotide primers hybridize are highly conserved.
- the amplifying step comprises polymerase chain reaction.
- the amplifying step comprises ligase chain reaction or strand displacement amplification.
- the bioagent is a bacterium, virus, parasite, fungi, cell or spore.
- the nucleic acid is ribosomal RNA.
- the nucleic acid encodes RNase P or an RNA-dependent RNA polymerase.
- the amplification product is ionized prior to molecular mass determination.
- the method may further comprise the step of isolating nucleic acid from the bioagent prior to contacting the nucleic acid with the at least one pair of oligonucleotide primers.
- the method may further comprise the step of performing steps a)-d) using a different oligonucleotide primer pair and comparing the results to one or more molecular mass amplification products obtained by performing steps a)-c) on a different plurality of known organisms from those in step d).
- the one or more molecular mass is contained in a database of molecular masses.
- the amplification product is ionized by electrospray ionization, matrix-assisted laser desorption or fast atom bombardment.
- the molecular mass is determined by mass spectrometry.
- the mass spectrometry is Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS), ion trap, quadrupole, magnetic sector, time of flight (TOF), Q-TOF or triple quadrupole.
- the method may further comprise performing step b) in the presence of an analog of adenine, thymidine, guanosine or cytidine having a different molecular weight than adenosine, thymidine, guanosine or cytidine.
- the oligonucleotide primer comprises a base analog or substitute base at positions 1 and 2 of each triplet within the primer, wherein the base analog or substitute base binds with increased affinity to its complement compared to the native base.
- the primer comprises a universal base at position 3 of each triplet within the primer.
- the base analog or substitute base may be 2,6-diaminopurine, propyne T, propyne G, phenoxazines or G-clamp.
- the universal base is inosine, guanidine, uridine, 5-nitroindole, 3-nitropyrrole, dP or dK, or 1-(2-deoxy- ⁇ -D-ribofuranosyl)-imidazole-4-carboxamide.
- Another embodiment of the present invention is a method of identifying an unknown bioagent in an animal sample comprising a) contacting nucleic acid from the bioagent with at least one pair of oligonucleotide primers that hybridize to sequences of the nucleic acid and flank a variable nucleic acid sequence; b) amplifying the variable nucleic acid sequence to produce an amplification product; c) determining the base composition of the amplification product; and d) comparing the base composition to one or more base compositions of amplification products obtained by performing steps a)-c) on a plurality of known organisms, wherein a match identifies the unknown bioagent in the animal sample.
- Animal samples include blood, bodily fluid and bodily tissue.
- the sequences to which the at least one pair of oligonucleotide primers hybridize are highly conserved.
- the amplifying step comprises polymerase chain reaction.
- the amplifying step comprises ligase chain reaction or strand displacement amplification.
- the bioagent is a bacterium, virus, parasite, fungi, cell or spore.
- the nucleic acid is ribosomal RNA.
- the nucleic acid encodes RNase P or an RNA-dependent RNA polymerase.
- the amplification product is ionized prior to molecular mass determination.
- the method may further comprise the step of isolating nucleic acid from the bioagent prior to contacting the nucleic acid with the at least one pair of oligonucleotide primers.
- the method may further comprise the step of performing steps a)-d) using a different oligonucleotide primer pair and comparing the results to one or more base composition signatures of amplification products obtained by performing steps a)-c) on a different plurality of known organisms from those in step d).
- the one or more base compositions is contained in a database of base compositions.
- the amplification product is ionized by clectrospray ionization, matrix-assisted laser desorption or fast atom bombardment.
- the molecular mass is determined by mass spectrometry.
- the mass spectrometry is Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS), ion trap, quadrupole, magnetic sector, time of flight (TOF), Q-TOF or triple quadrupole.
- the method may further comprise performing step b) in the presence of an analog of adenine, thymidine, guanosine or cytidine having a different molecular weight than adenosine, thymidine, guanosine or cytidine.
- the oligonucleotide primer comprises a base analog or substitute base at positions 1 and 2 of each triplet within the primer, wherein the base analog or substitute base binds with increased affinity to its complement compared to the native base.
- the primer comprises a universal base at position 3 of each triplet within the primer.
- the base analog or substitute base may be 2,6-diaminopurine, propyne T, propyne G, phenoxazines or G-clamp.
- the universal base is inosine, guanidine, uridine, 5-nitroindole, 3-nitropyrrole, dP or dK, or 1-(2-deoxy- ⁇ -D-ribofuranosyl)-imidazole-4-carboxamide.
- FIG. 1A- 1 H and FIG. 2 are consensus diagrams that show examples of conserved regions from 16S rRNA (FIG. 1A, 1 A- 2 , 1 A- 3 , 1 A- 4 , 1 B, 1 B- 1 , and 1 B- 21 ), 23S rRNA (3′-half, FIG. 1C- 1 , 1 C- 2 , and ID; 5′-half, FIG. 1E-F), 23S rRNA Domain I (FIG. 1G), 23S rRNA Domain IV (FIG. 1H) and 16S rRNA Domain III (FIG. 2) which are suitable for use in the present invention.
- FIG. 2 shows a typical primer amplified region from the 16S rRNA Domain III shown in FIG. 1C.
- FIG. 3 is a schematic diagram showing conserved regions in RNase P. Bases in capital letters are greater than 90% conserved; bases in lower case letters are 80-90% conserved; filled circles designate bases which are 70-80% conserved; and open circles designate bases that are less than 70% conserved.
- FIG. 4 is a schematic diagram of base composition signature determination using nucleotide analog “tags” to determine base composition signatures.
- FIG. 5 shows the deconvoluted mass spectra of a Bacillus anthracis region with and without the mass tag phosphorothioate A (A*).
- the two spectra differ in that the measured molecular weight of the mass tag-containing sequence is greater than the unmodified sequence.
- FIG. 6 shows base composition signature (BCS) spectra from PCR products from Staphylococcus aureus ( S. aureus 16S — 1337F) and Bacillus anthracus ( B. anthr . 16S — 1337F), amplified using the same primers.
- the two strands differ by only two (AT ⁇ CG) substitutions and are clearly distinguished on the basis of their BCS.
- FIG. 7 shows that a single difference between two sequences (A 14 in B. anthracis vs. A 15 in B. cereus ) can be easily detected using ESI-TOF mass spectrometry.
- FIG. 8 is an ESI-TOF of Bacillus anthracis spore coat protein sspE 56mer plus calibrant. The signals unambiguously identify B. anthracis versus other Bacillus species.
- FIG. 9 is an ESI-TOF of a B. anthracis synthetic 16S — 1228 duplex (reverse and forward strands). The technique easily distinguishes between the forward and reverse strands.
- FIG. 10 is an ESI-FTICR-MS of a synthetic B. anthracis 16S — 1337 46 base pair duplex.
- FIG. 11 is an ESI-TOF-MS of a 56mer oligonucleotide (3 scans) from the B. anthracis saspB gene with an internal mass standard.
- the internal mass standards are designated by asterisks.
- FIG. 12 is an ESI-TOF-MS of an internal standard with 5 mM TBA-TFA buffer showing that charge stripping with tributylammonium trifluoroacetate reduces the most abundant charge state from [M-8H + ] 8 ⁇ to [M-3H + ] 3 ⁇ .
- the present invention provides a combination of a non-PCR biomass detection mode, preferably high-resolution MS, with PCR-based BCS or mass technology using “intelligent primers” which hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent.
- the high-resolution MS technique is used to determine the molecular mass and/or base composition signature (BCS) of the amplified sequence region.
- This unique mass or unique “base composition signature” (BCS) is then input to a maximum-likelihood detection algorithm for matching against a database of masses or base composition signatures in the same amplified region.
- the present method combines PCR-based amplification technology (which provides specificity) and a molecular mass detection mode (which provides speed and does not require nucleic acid sequencing of the amplified target sequence) for bioagent detection and identification.
- the present method allows extremely rapid and accurate detection and identification of bioagents compared to existing methods. Furthermore, this rapid detection and identification is possible even when sample material is impure.
- the method leverages ongoing biomedical research in virulence, pathogenicity, drug resistance and genome sequencing into a method which provides greatly improved sensitivity, specificity and reliability compared to existing methods, with lower rates of false positives.
- the methods are useful in a wide variety of fields, including, but not limited to, those fields discussed below.
- the methods disclosed herein can be used for environmental testing. Detection and discrimination of pathogenic vs. non-pathogenic bacteria, viruses, parasites, fungi and the like, in samples of water, land, air, or other samples, can be carried out.
- Water samples can be obtained from, for example, lakes, rivers, oceans, streams, water treatment systems, rainwater, groundwater, water table, reservoirs, wells, bottled water, and the like.
- Air samples can be obtained from ventilation systems, airplane cabins, schools, hospitals, mass transit locations such as subways, train stations, airports, and the like. Conditions such as sick building syndrome can be detected.
- Land samples can be obtained from any location.
- the methods disclosed herein can be used to screen blood and other bodily fluids and tissues for pathogenic and non-pathogenic bacteria, viruses, parasites, fungi and the like.
- Animal samples including but not limited to, blood and other bodily fluid and tissue samples, can be obtained from living animals, who are either known or not known to or suspected of having a disease, infection, or condition. Alternately, animal samples such as blood and other bodily fluid and tissue samples can be obtained from deceased animals. Blood samples can be further separated into plasma or cellular fractions and further screened as desired. Bodily fluids and tissues can be obtained from any part of the animal or human body. Animal samples can be obtained from, for example, mammals and humans.
- the methods disclosed herein can be used for forensics.
- medical examiners can use the present invention to determine the cause of death.
- epidemiologists for example, can use the present methods to determine the geographic origin of a particular strain of bacteria or virus.
- a particular strain of bacteria or virus may have a sequence difference that is associated with a particular area of a country or the world and identification of such a sequence difference can lead to the identification of the geographic origin and epidemiological tracking of the spread of the particular disease, disorder or condition associated with the detected virus or bacteria.
- carriers of particular DNA or diseases such as mammals, non-mammals, birds, insects, and plants, can be tracked by screening SNPs, VNTRs, or polyA, for example.
- Diseases, such as malaria can be tracked by screening commensals, such as mosquitos.
- the methods disclosed herein can be used for detecting the presence of pathogenic and non-pathogenic bacteria, viruses, parasites, fungi and the like in samples of foodstuff or cosmetics.
- food and wine can be examined for the presence of pathogenic and non-pathogenic bacteria, viruses, parasites, fungi and the like.
- Particular types of foods susceptible to bioagent contamination such as agricultural products, meat products and eggs, can be examined for pathogenic organisms such as E. coli and Salmonella species.
- Such examination procedures can be used by, for example, the wholesalers of foodstuffs and beverages, or by regulatory agencies such as the U.S. Department of Agriculture and the Food and Drug Administration.
- grapes and wines for example, can be examined using the present methods to detect particular strains of bacteria or yeast that may indicate a particular time upon which to harvest the grapes or alter the wine-making process.
- the methods disclosed herein can be used for detecting the presence of bioagents in a container, such as a package, box, envelope, mail tube, railroad box car, and the like.
- a container such as a package, box, envelope, mail tube, railroad box car, and the like.
- mail and package delivery entities and agencies both domestic and abroad, as well investigative agencies such as the FBI and ATF can use the present methods to detect bioagents in containers.
- the methods disclosed herein can be used for detecting the presence of pathogenic and non-pathogenic bacteria, viruses, parasites, fungi and the like in organ donors and/or in organs from donors. Such examination can result in the prevention of the transfer of, for example, viruses such as West Nile virus, hepatitis viruses, human immunodeficiency virus, and the like from a donor to a recipient via a transplanted organ.
- the methods disclosed herein can also be used for detection of host versus graft or graft versus host rejection issues related to organ donors by detecting the presence of particular antigens in either the graft or host known or suspected of causing such rejection.
- the bioagents in this regard are the antigens of the major histocompatibility complex, such as the HLA antigens.
- the methods disclosed herein can be used for detection and identification of livestock infections such as, for example, mad cow disease, hoof and mouth disease, and the like.
- Livestock includes, but is not limited to, cows, pigs, sheep, chickens, turkeys, goats, and other farm animals.
- the methods disclosed herein can be used for pharmacogenetic analysis and medical diagnosis including, but not limited to, cancer diagnosis based on mutations and polymorphisms, drug resistance and susceptibility testing, screening for and/or diagnosis of genetic diseases and conditions, and diagnosis of infectious diseases and conditions.
- the present methods can also be used to detect and track emerging infectious diseases, such as West Nile virus infection, mad cow disease, and HIV-related diseases.
- the present methods can be used to detect and classify any biological agent, including bacteria, viruses, fungi and toxins.
- the information obtained is used to determine practical information needed for countermeasures, including toxin genes, pathogenicity islands and antibiotic resistance genes.
- the methods can be used to identify natural or deliberate engineering events including chromosome fragment swapping, molecular breeding (gene shuffling) and emerging infectious diseases.
- Bacteria have a common set of absolutely required genes. About 250 genes are present in all bacterial species ( Proc. Natl. Acad. Sci. U.S.A . 93:10268, 1996 ; Science 270:397, 1995), including tiny genomes like Mycoplasma, Ureaplasma and Rickettsia. These genes encode proteins involved in translation, replication, recombination and repair, transcription, nucleotide metabolism, amino acid metabolism, lipid metabolism, energy generation, uptake, secretion and the like.
- Operons can also be targeted using the present method.
- One example of an operon is the bfp operon from enteropathogenic E. coli .
- Multiple core chromosomal genes can be used to classify bacteria at a genus or genus species level to determine if an organism has threat potential. The method can also be used to detect pathogenicity markers (plasmid or chromosomal) and antibiotic resistance genes to confirm the threat potential of an organism and to direct countermeasures.
- a theoretically ideal bioagent detector would identify, quantify, and report the complete nucleic acid sequence of every bioagent that reached the sensor.
- the complete sequence of the nucleic acid component of a pathogen would provide all relevant information about the threat, including its identity and the presence of drug-resistance or pathogenicity markers. This ideal has not yet been achieved.
- the present invention provides a straightforward strategy for obtaining information with the same practical value using base composition signatures (BCS). While the base composition of a gene fragment is not as information-rich as the sequence itself, there is no need to analyze the complete sequence of the gene if the short analyte sequence fragment is properly chosen.
- BCS base composition signatures
- a database of reference sequences can be prepared in which each sequence is indexed to a unique base composition signature, so that the presence of the sequence can be inferred with accuracy from the presence of the signature.
- base composition signatures are that they can be quantitatively measured in a massively parallel fashion using multiplex PCR (PCR in which two or more primer pairs amplify target sequences simultaneously) and mass spectrometry. These multiple primer amplified regions uniquely identify most threat and ubiquitous background bacteria and viruses. In addition, cluster-specific primer pairs distinguish important local clusters (e.g., anthracis group).
- a “bioagent” is any organism, living or dead, or a nucleic acid derived from such an organism.
- bioagents include but are not limited to cells (including but not limited to human clinical samples, bacterial cells and other pathogens) viruses, parasites, fungi, toxin genes and bioregulating compounds. Samples may be alive or dead or in a vegetative state (for example, vegetative bacteria or spores) and may be encapsulated or bioengineered.
- a “base composition signature” is the exact base composition from selected fragments of nucleic acid sequences that uniquely identifies the target gene and source organism. BCS can be thought of as unique indexes of specific genes.
- integer primers are primers which bind to sequence regions which flank an intervening variable region.
- these sequence regions which flank the variable region are highly conserved among different species of bioagent.
- the sequence regions may be highly conserved among all Bacillus species.
- highly conserved it is meant that the sequence regions exhibit between about 80-100%, more preferably between about 90-100% and most preferably between about 95-100% identity.
- FIGS. 1 A- 1 I A typical primer amplified region in 16S rRNA is shown in FIG. 2.
- the arrows represent primers which bind to highly conserved regions which flank a variable region in 16S rRNA domain III.
- the amplified region is the stem-loop structure under “1100-1188.”
- One main advantage of the detection methods of the present invention is that the primers need not be specific for a particular bacterial species, or even genus, such as Bacillus or Streptomyces. Instead, the primers recognize highly conserved regions across hundreds of bacterial species including, but not limited to, the species described herein. Thus, the same primer pair can be used to identify any desired bacterium because it will bind to the conserved regions which flank a variable region specific to a single species, or common to several bacterial species, allowing nucleic acid amplification of the intervening sequence and determination of its molecular weight and base composition.
- primers used in the present method bind to one or more of these regions or portions thereof.
- the present invention provides a combination of a non-PCR biomass detection mode, preferably high-resolution MS, with nucleic acid amplification-based BCS technology using “intelligent primers” which hybridize to conserved regions and which bracket variable regions that uniquely identify the bioagent(s).
- a non-PCR biomass detection mode preferably high-resolution MS
- nucleic acid amplification-based BCS technology using “intelligent primers” which hybridize to conserved regions and which bracket variable regions that uniquely identify the bioagent(s).
- PCR ligase chain reaction
- SDA strand displacement amplification
- the high-resolution MS technique allows separation of bioagent spectral lines from background spectral lines in highly cluttered environments.
- the resolved spectral lines are then translated to BCS which are input to a maximum-likelihood detection algorithm matched against spectra for one or more known BCS.
- the bioagent BCS spectrum is matched against one or more databases of BCS from vast numbers of bioagents.
- base composition signatures are quantitatively measured in a massively parallel fashion using the polymerase chain reaction (PCR), preferably multiplex PCR, and mass spectrometric (MS) methods. Sufficient quantities of nucleic acids must be present for detection of bioagents by MS. A wide variety of techniques for preparing large amounts of purified nucleic acids or fragments thereof are well known to those of skill in the art.
- PCR requires one or more pairs of oligonucleotide primers which bind to regions which flank the target sequence(s) to be amplified. These primers prime synthesis of a different strand of DNA, with synthesis occurring in the direction of one primer towards the other primer.
- the primers, DNA to be amplified, a thermostable DNA polymerase (e.g. Taq polymerase), the four deoxynucleotide triphosphates, and a buffer are combined to initiate DNA synthesis.
- the solution is denatured by heating, then cooled to allow annealing of newly added primer, followed by another round of DNA synthesis. This process is typically repeated for about 30 cycles, resulting in amplification of the target sequence.
- the “intelligent primers” define the target sequence region to be amplified and analyzed.
- the target sequence is a ribosomal RNA (rRNA) gene sequence.
- rRNA ribosomal RNA
- rRNA genes Like many genes involved in core life functions, rRNA genes contain sequences that are extraordinarily conserved across bacterial domains interspersed with regions of high variability that are more specific to each species. The variable regions can be utilized to build a database of base composition signatures.
- the strategy involves creating a structure-based alignment of sequences of the small (16S) and the large (23S) subunits of the rRNA genes. For example, there are currently over 13,000 sequences in the ribosomal RNA database that has been created and maintained by Robin Gutell, University of Texas at Austin, and is publicly available on the Institute for Cellular and Molecular Biology web page (www.rna.icmb.utexas.edu/). There is also a publicly available rRNA database created and maintained by the University of Antwerp, Belgium at www.rrna.uia.ac.be.
- regions that are useful as base composition signatures are: a) between about 80 and 100%, preferably>about 95% identity among species of the particular bioagent of interest, of upstream and downstream nucleotide sequences which serve as sequence amplification primer sites; b) an intervening variable region which exhibits no greater than about 5% identity among species; and c) a separation of between about 30 and 1000 nucleotides, preferably no more than about 50-250 nucleotides, and more preferably no more than about 60-100 nucleotides, between the conserved regions.
- flanking rRNA primer sequences serve as good “universal” primer binding sites to amplify the region of interest for most, if not all, bacterial species.
- the intervening region between the sets of primers varies in length and/or composition, and thus provides a unique base composition signature.
- oligonucleotide primers can be designed such that the nucleotide corresponding to this position is a base which can bind to more than one nucleotide, referred to herein as a “universal base”.
- inosine (I) binds to U, C or A; guanine (G) binds to U or C, and uridine (U) binds to U or C.
- Other examples of universal bases include nitroindoles such as 5-nitroindole or 3-nitropyrrole (Loakes et al., Nucleosides and Nucleotides 14:1001-1003, 1995), the degenerate nucleotides dP or dK (Hill et al.), an acyclic nucleoside analog containing 5-nitroindazole (Van Aerschot et al., Nucleosides and Nucleotides 14:1053-1056, 1995) or the purine analog 1-(2-deoxy- ⁇ -D-ribofuranosyl)-imidazole-4-carboxamide (Sala et al., Nucl. Acids Res. 24:3302-3306, 1996).
- the oligonucleotide primers are designed such that the first and second positions of each triplet are occupied by nucleotide analogs which bind with greater affinity than the unmodified nucleotide.
- these analogs are 2,6-diaminopurine which binds to thymine, propyne T which binds to adenine and propyne C and phenoxazines, including G-clamp, which binds to G.
- Propynes are described in U.S. Pat. Nos. 5,645,985, 5,830.653 and 5,484,908, the entire contents of which are incorporated herein by reference.
- Phenoxazines are described in U.S. Pat. Nos. 5,502,177, 5,763,588, and 6,005,096, the entire contents of which are incorporated herein by reference.
- G-clamps are described in U.S. Pat. Nos. 6,007,992 and 6,028,183, the entire contents of which are incorporated herein by reference.
- Bacterial biological warfare agents capable of being detected by the present methods include Bacillus anthracis (anthrax), Yersinia pestis (pneumonic plague), Franciscella tularensis (tularemia), Brucella suis, Brucella abortus, Brucella melitensis (undulant fever), Burkholderia mallei (glanders), Burkholderia pseudomalleii (melioidosis), Salmonella typhi (typhoid fever), Rickettsia typhii (epidemic typhus), Rickettsia prowasekii (endemic typhus) and Coxiella burnetii (Q fever), Rhodobacter capsulatus, Chlamydia pneumoniae, Escherichia coli, Shigella dysenteriae, Shigella
- target regions suitable for use in the present invention for detection of bacteria include 5S rRNA and RNase P (FIG. 3).
- Biological warfare fungus biowarfare agents include coccidioides immitis (Coccidioidomycosis).
- Biological warfare toxin genes capable of being detected by the methods of the present invention include botulism, T-2 mycotoxins, ricin, staph enterotoxin B, shigatoxin, abrin, aflatoxin, Clostridium perfringens epsilon toxin, conotoxins, diacetoxyscirpenol, tetrodotoxin and saxitoxin.
- RNA viruses positive-strand and negative-strand
- Every RNA virus is a family of related viruses (quasispecies). These viruses mutate rapidly and the potential for engineered strains (natural or deliberate) is very high.
- RNA viruses cluster into families that have conserved RNA structural domains on the viral genome (e.g., virion components, accessory proteins) and conserved housekeeping genes that encode core viral proteins including, for single strand positive strand RNA viruses, RNA-dependent RNA polymerase, double stranded RNA helicase, chymotrypsin-like and papain-like proteases and methyltransferases.
- Examples of ( ⁇ )-strand RNA viruses include arenaviruses (e.g., sabia virus, lassa fever, Machupo, Argentine hemorrhagic fever, flexal virus), bunyaviruses (e.g., hantavirus, nairovirus, phlebovirus, hantaan virus, Congo-crimean hemorrhagic fever, rift valley fever), and mononegavirales (e.g., filovirus, paramyxovirus, ebola virus, Marburg, equine morbillivirus).
- arenaviruses e.g., sabia virus, lassa fever, Machupo, Argentine hemorrhagic fever, flexal virus
- bunyaviruses e.g., hantavirus, nairovirus, phlebovirus, hantaan virus, Congo-crimean hemorrhagic fever, rift valley fever
- (+)-strand RNA viruses include picornaviruses (e.g., coxsackievirus, echovirus, human coxsackievirus A, human echovirus, human enterovirus, human poliovirus, hepatitis A virus, human parechovirus, human rhinovirus), astroviruses (e.g., human astrovirus), calciviruses (e.g., chiba virus, chitta virus, human calcivirus, norwalk virus), nidovirales (e.g., human coronavirus, human torovirus), flaviviruses (e.g., dengue virus 1-4, Japanese encephalitis virus, Kyanasur forest disease virus, Murray Valley encephalitis virus, Rocio virus, St.
- picornaviruses e.g., coxsackievirus, echovirus, human coxsackievirus A, human echovirus, human enterovirus, human poliovirus, hepatitis A virus, human pare
- the hepatitis C virus has a 5′-untranslated region of 340 nucleotides, an open reading frame encoding 9 proteins having 3010 amino acids and a 3′-untranslated region of 240 nucleotides.
- the 5′-UTR and 3′-UTR are 99% conserved in hepatitis C viruses.
- the target gene is an RNA-dependent RNA polymerase or a helicase encoded by (+)-strand RNA viruses, or RNA polymerase from a ( ⁇ )-strand RNA virus.
- (+)-strand RNA viruses are double stranded RNA and replicate by RNA-directed RNA synthesis using RNA-dependent RNA polymerase and the positive strand as a template. Helicase unwinds the RNA duplex to allow replication of the single stranded RNA.
- viruses include viruses from the family picornaviridae (e.g., poliovirus, coxsackievirus, echovirus), togaviridae (e.g., alphavirus, flavivirus, rubivirus), arenaviridae (e.g., lymphocytic choriomeningitis virus, lassa fever virus), cononaviridae (e.g., human respiratory virus) and Hepatitis A virus.
- picornaviridae e.g., poliovirus, coxsackievirus, echovirus
- togaviridae e.g., alphavirus, flavivirus, rubivirus
- arenaviridae e.g., lymphocytic choriomeningitis virus, lassa fever virus
- cononaviridae e.g., human respiratory virus
- Hepatitis A virus e.g., human respiratory virus
- the detection scheme for the PCR products generated from the bioagent(s) incorporates three features. First, the technique simultaneously detects and differentiates multiple (generally about 6-10) PCR products. Second, the technique provides a BCS that uniquely identifies the bioagent from the possible primer sites. Finally, the detection technique is rapid, allowing multiple PCR reactions to be run in parallel.
- the method can be used to detect the presence of antibiotic resistance and/or toxin genes in a bacterial species.
- Bacillus anthracis comprising a tetracycline resistance plasmid and plasmids encoding one or both anthracis toxins (px01 and/or px02) can be detected by using antibiotic resistance primer sets and toxin gene primer sets. If the B. anthracis is positive for tetracycline resistance, then a different antibiotic, for example quinalone, is used.
- Mass spectrometry (MS)-based detection of PCR products provides all of these features with additional advantages.
- MS is intrinsically a parallel detection scheme without the need for radioactive or fluorescent labels, since every amplification product with a unique base composition is identified by its molecular mass.
- the current state of the art in mass spectrometry is such that less than femtomole quantities of material can be readily analyzed to afford information about the molecular contents of the sample.
- An accurate assessment of the molecular mass of the material can be quickly obtained, irrespective of whether the molecular weight of the sample is several hundred, or in excess of one hundred thousand atomic mass units (amu) or Daltons.
- Intact molecular ions can be generated from amplification products using one of a variety of ionization techniques to convert the sample to gas phase. These ionization methods include, but are not limited to, electrospray ionization (ES), matrix-assisted laser desorption ionization (MALDI) and fast atom bombardment (FAB).
- ES electrospray ionization
- MALDI matrix-assisted laser desorption ionization
- FAB fast atom bombardment
- MALDI of nucleic acids along with examples of matrices for use in MALDI of nucleic acids, are described in WO 98/54751 (Genetrace, Inc.).
- large DNAs and RNAs, or large amplification products therefrom can be digested with restriction endonucleases prior to ionization.
- restriction endonucleases for example, an amplification product that was 10 kDa could be digested with a series of restriction endonucleases to produce a panel of, for example, 100 Da fragments. Restriction endonucleases and their sites of action are well known to the skilled artisan. In this manner, mass spectrometry can be performed for the purposes of restriction mapping.
- Electrospray ionization mass spectrometry is particularly useful for very high molecular weight polymers such as proteins and nucleic acids having molecular weights greater than 10 kDa, since it yields a distribution of multiply-charged molecules of the sample without causing a significant amount of fragmentation.
- the mass detectors used in the methods of the present invention include, but are not limited to, Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS), ion trap, quadrupole, magnetic sector, time of flight (TOF), Q-TOF, and triple quadrupole.
- FT-ICR-MS Fourier transform ion cyclotron resonance mass spectrometry
- ion trap ion trap
- quadrupole quadrupole
- magnetic sector magnetic sector
- TOF time of flight
- Q-TOF Q-TOF
- triple quadrupole triple quadrupole
- the mass spectrometric techniques which can be used in the present invention include, but are not limited to, tandem mass spectrometry, infrared multiphoton dissociation and pyrolytic gas chromatography mass spectrometry (PGC-MS).
- the bioagent detection system operates continually in bioagent detection mode using pyrolytic GC-MS without PCR for rapid detection of increases in biomass (for example, increases in fecal contamination of drinking water or of germ warfare agents).
- a continuous sample stream flows directly into the PGC-MS combustion chamber.
- a PCR process is automatically initiated.
- Bioagent presence produces elevated levels of large molecular fragments from 100-7,000 Da which are observed in the PGC-MS spectrum.
- the observed mass spectrum is compared to a threshold level and when levels of biomass are determined to exceed a predetermined threshold, the bioagent classification process described hereinabove(combining PCR and MS, preferably FT-ICR MS) is initiated.
- alarms or other processes are also initiated by this detected biomass level.
- tandem mass spectrometry (MS n ) techniques may provide more definitive information pertaining to molecular identity or sequence.
- Tandem MS involves the coupled use of two or more stages of mass analysis where both the separation and detection steps are based on mass spectrometry. The first stage is used to select an ion or component of a sample from which further structural information is to be obtained. The selected ion is then fragmented using, e.g., blackbody irradiation, infrared multiphoton dissociation, or collisional activation. For example, ions generated by electrospray ionization (ESI) can be fragmented using IR multiphoton dissociation.
- ESI electrospray ionization
- This activation leads to dissociation of glycosidic bonds and the phosphate backbone, producing two series of fragment ions, called the w-series (having an intact 3′ terminus and a 5′ phosphate following internal cleavage) and the ⁇ -Base series(having an intact 5′ terminus and a 3′ furan).
- the second stage of mass analysis is then used to detect and measure the mass of these resulting fragments of product ions.
- Such ion selection followed by fragmentation routines can be performed multiple times so as to essentially completely dissect the molecular sequence of a sample.
- a nucleotide analog or “tag” is incorporated during amplification (e.g., a 5-(trifluoromethyl) deoxythymidine triphosphate) which has a different molecular weight than the unmodified base so as to improve distinction of masses.
- tags are described in, for example, PCT WO97/33000. This further limits the number of possible base compositions consistent with any mass.
- 5-(trifluoromethyl)deoxythymidine triphosphate can be used in place of dTTP in a separate nucleic acid amplification reaction.
- Measurement of the mass shift between a conventional amplification product and the tagged product is used to quantitate the number of thymidine nucleotides in each of the single strands. Because the strands are complementary, the number of adenosine nucleotides in each strand is also determined.
- the number of G and C residues in each strand is determined using, for example, the cytidine analog 5-methylcytosine (5-meC) or propyne C.
- the mass tag phosphorothioate A (A*) was used to distinguish a Bacillus anthracis cluster.
- the B. anthracis (A 14 G 9 C 14 T 9 ) had an average MW of 14072.26, and the B. anthracis (A 1 A* 13 G 9 C 14 T 9 ) had an average molecular weight of 14281.11 and the phosphorothioate A had an average molecular weight of +16.06 as determined by ESI-TOF MS.
- the deconvoluted spectra are shown in FIG. 5.
- Signals from the mass spectrometer may be input to a maximum-likelihood detection and classification algorithm such as is widely used in radar signal processing.
- the detection processing uses matched filtering of BCS observed in mass-basecount space and allows for detection and subtraction of signatures from known, harmless organisms, and for detection of unknown bioagent threats. Comparison of newly observed bioagents to known bioagents is also possible, for estimation of threat level, by comparing their BCS to those of known organisms and to known forms of pathogenicity enhancement, such as insertion of antibiotic resistance genes or toxin genes.
- Processing may end with a Bayesian classifier using log likelihood ratios developed from the observed signals and average background levels.
- the program emphasizes performance predictions culminating in probability-of-detection versus probability-of-false-alarm plots for conditions involving complex backgrounds of naturally occurring organisms and environmental contaminants.
- Matched filters consist of a priori expectations of signal values given the set of primers used for each of the bioagents.
- a genomic sequence database e.g. GenBank
- GenBank is used to define the mass basecount matched filters.
- the database contains known threat agents and benign background organisms. The latter is used to estimate and subtract the signature produced by the background organisms.
- a maximum likelihood detection of known background organisms is implemented using matched filters and a running-sum estimate of the noise covariance.
- a strategy to “triangulate” each organism by measuring signals from multiple core genes is used to reduce false negative and false positive signals, and enable reconstruction of the origin or hybrid or otherwise engineered bioagents.
- alignments are created from nucleic acid sequence databases. The alignments are then analyzed for regions of conservation and variation, and potential primer binding sites flanking variable regions are identified.
- amplification target regions for signature analysis are selected which distinguishes organisms based on specific genomic differences (i.e., base composition). For example, detection of signatures for the three part toxin genes typical of B. anthracis (Bowen, J. E. and C. P. Quinn, J Appl. Microbiol . 1999, 87, 270-278) in the absence of the expected signatures from the B. anthracis genome would suggest a genetic engineering event.
- the present method can also be used to detect single nucleotide polymorphisms (SNPs), or multiple nucleotide polymorphisms, rapidly and accurately.
- SNP single nucleotide polymorphisms
- a SNP is defined as a single base pair site in the genome that is different from one individual to another. The difference can be expressed either as a deletion, an insertion or a substitution, and is frequently linked to a disease state. Because they occur every 100-1000 base pairs, SNPs are the most frequently bound type of genetic marker in the human genome.
- sickle cell anemia results from an A-T transition, which encodes a valine rather than a glutamic acid residue.
- Oligonucleotide primers may be designed such that they bind to sequences that flank a SNP site, followed by nucleotide amplification and mass determination of the amplified product. Because the molecular masses of the resulting product from an individual who does not have sickle cell anemia is different from that of the product from an individual who has the disease, the method can be used to distinguish the two individuals. Thus, the method can be used to detect any known SNP in an individual and thus diagnose or determine increased susceptibility to a disease or condition.
- blood is drawn from an individual and peripheral blood mononuclear cells (PBMC) are isolated and simultaneously tested, preferably in a high-throughput screening method, for one or more SNPs using appropriate primers based on the known sequences which flank the SNP region.
- PBMC peripheral blood mononuclear cells
- the National Center for Biotechnology Information maintains a publicly available database of SNPs (www.ncbi.nlm.nih.gov/SNP/).
- the method of the present invention can also be used for blood typing.
- the gene encoding A, B or O blood type can differ by four single nucleotide polymorphisms. If the gene contains the sequence CGTGGTGACCCTT (SEQ ID NO:5), antigen A results. If the gene contains the sequence CGTCGTCACCGCTA (SEQ ID NO:6) antigen B results. If the gene contains the sequence CGTGGT-ACCCCTT (SEQ ID NO:7), blood group O results (“ ⁇ ” indicates a deletion). These sequences can be distinguished by designing a single primer pair that flanks these regions, followed by amplification and mass determination.
- all of the aformentioned methods can be used to determine or confirm the absence of a bioagent in a sample. For example, when the molecular mass or base composition is compared to one or more molecular masses or base compositions obtained from a plurality of known organisms and no match is obtained, the absence of a particular bioagent is determined or confirmed.
- a positive control can be used to confirm the integrity of the system. Such positive controls include, but are not limited to addition of a known bioagent to the sample and confirming the presence of the known bioagent in the sample by obtaining a match from the comparison step. Alternately, residual primer signal can be detected, thus indicating that the system integrity is intact.
- nucleic acid is isolated from the organisms and amplified by PCR using standard methods prior to BCS determination by mass spectrometry.
- Nucleic acid is isolated, for example, by detergent lysis of bacterial cells, centrifugation and ethanol precipitation. Nucleic acid isolation methods are described in, for example, Current Protocols in Molecular Biology (Ausubel et al.) and Molecular Cloning; A Laboratory Manual (Sambrook et al.).
- the nucleic acid is then amplified using standard methodology, such as PCR, with primers which bind to conserved regions of the nucleic acid which contain an intervening variable sequence as described below.
- FTICR Instrumentation The FTICR instrument is based on a 7 tesla actively shielded superconducting magnet and modified Bruker Daltonics Apex II 70e ion optics and vacuum chamber. The spectrometer is interfaced to a LEAP PAL autosampler and a custom fluidics control system for high throughput screening applications. Samples are analyzed directly from 96-well or 384-well microtiter plates at a rate of about 1 sample/minute.
- the Bruker data-acquisition platform is supplemented with a lab-built ancillary NT datastation which controls the autosampler and contains an arbitrary waveform generator capable of generating complex rf-excite waveforms (frequency sweeps, filtered noise, stored waveform inverse Fourier transform (SWIFT), etc.) for sophisticated tandem MS experiments.
- a lab-built ancillary NT datastation which controls the autosampler and contains an arbitrary waveform generator capable of generating complex rf-excite waveforms (frequency sweeps, filtered noise, stored waveform inverse Fourier transform (SWIFT), etc.) for sophisticated tandem MS experiments.
- SWIFT stored waveform inverse Fourier transform
- Modified ESI Source In sample-limited analyses, analyte solutions are delivered at 150 nL/minute to a 30 mm i.d. fused-silica ESI emitter mounted on a 3-D micromanipulator.
- the ESI ion optics consists of a heated metal capillary, an rf-only hexapole, a skimmer cone, and an auxiliary gate electrode.
- the 6.2 cm rf-only hexapole is comprised of 1 mm diameter rods and is operated at a voltage of 380 Vpp at a frequency of 5 MHz.
- a lab-built electro-mechanical shutter can be employed to prevent the electrospray plume from entering the inlet capillary unless triggered to the “open” position via a TTL pulse from the data station.
- a stable electrospray plume is maintained between the ESI emitter and the face of the shutter.
- the back face of the shutter arm contains an elastomeric seal that can be positioned to form a vacuum seal with the inlet capillary. When the seal is removed, a 1 mm gap between the shutter blade and the capillary inlet allows constant pressure in the external ion reservoir regardless of whether the shutter is in the open or closed position.
- a “time slice” of ions is allowed to enter the inlet capillary and is subsequently accumulated in the external ion reservoir.
- the rapid response time of the ion shutter ( ⁇ 25 ms) provides reproducible, user defined intervals during which ions can be injected into and accumulated in the external ion reservoir.
- Apparatus for Infrared Multiphoton Dissociation A 25 watt CW CO 2 laser operating at 10.6 ⁇ m has been interfaced to the spectrometer to enable infrared multiphoton dissociation (IRMPD) for oligonucleotide sequencing and other tandem MS applications.
- An aluminum optical bench is positioned approximately 1.5 m from the actively shielded superconducting magnet such that the laser beam is aligned with the central axis of the magnet.
- the unfocused 3 mm laser beam is aligned to traverse directly through the 3.5 mm holes in the trapping electrodes of the FTICR trapped ion cell and longitudinally traverse the hexapole region of the external ion guide finally impinging on the skimmer cone.
- This scheme allows IRMPD to be conducted in an m/z selective manner in the trapped ion cell (e.g. following a SWIFT isolation of the species of interest), or in a broadband mode in the high pressure region of the external ion reservoir where collisions with neutral molecules stabilize IRMPD-generated metastable fragment ions resulting in increased fragment ion yield and sequence coverage.
- Table 1 shows a small cross section of a database of calculated molecular masses for over 9 primer sets and approximately 30 organisms.
- the primer sets were derived from rRNA alignment. Examples of regions from rRNA consensus alignments are shown in FIGS. 1 A- 1 C. Lines with arrows are examples of regions to which intelligent primer pairs for PCR are designed.
- the primer pairs are >95% conserved in the bacterial sequence database (currently over 10,000 organisms).
- the intervening regions are variable in length and/or composition, thus providing the base composition “signature” (BCS) for each organism.
- Primer pairs were chosen so the total length of the amplified region is less than about 80-90 nucleotides.
- the label for each primer pair represents the starting and ending base number of the amplified region on the consensus diagram.
- FIG. 6 shows the use of ESI-FT-ICR MS for measurement of exact mass.
- the spectra from 46mer PCR products originating at position 1337 of the 16S rRNA from S. aureus (upper) and B. anthracis (lower) are shown. These data are from the region of the spectrum containing signals from the [M-8H+] 8 ⁇ charge states of the respective 5′-3′ strands.
- the two strands differ by two (AT ⁇ CG) substitutions, and have measured masses of 14206.396 and 14208.373 ⁇ 0.010 Da, respectively.
- the possible base compositions derived from the masses of the forward and reverse strands for the B. anthracis products are listed in Table 3. TABLE 3 Possible base composition for B.
- the pathogen Vibrio cholera can be distinguished from Vibrio parahemolyticus with ⁇ M>600 Da using one of three 16S primer sets shown in Table 2 (16S — 971, 16S — 1228 or 16S — 1294) as shown in Table 4.
- the two mycoplasma species in the list ( M. genitalium and M. pneumoniae ) can also be distinguished from each other, as can the three mycobacteriae. While the direct mass measurements of amplified products can identify and distinguish a large number of organisms, measurement of the base composition signature provides dramatically enhanced resolving power for closely related organisms.
- compositional analysis or fragmentation patterns are used to resolve the differences.
- the single base difference between the two organisms yields different fragmentation patterns, and despite the presence of the ambiguous/unidentified base N at position 20 in B. anthracis , the two organisms can be identified.
- Tables 4a-b show examples of primer pairs from Table 1 which distinguish pathogens from background.
- Table 4 shows the expected molecular weight and base composition of region 16S — 1100-1188 in Mycobacterium avium and Streptomyces sp. TABLE 5 Organism Molecular Region name Length weight Base comp. 16S — Mycobacterium 82 25624.1728 A 16 G 32 C 18 T 16 1100-1188 avium 16S — Streptomyces 96 29904.871 A 17 G 38 C 27 T 14 1100-1188 sp.
- Table 5 shows base composition (single strand) results for 16S — 1100-1188 primer amplification reactions different species of bacteria. Species which are repeated in the table (e.g., Clostridium botulinum) are different strains which have different base compositions in the 16S — 1100-1188 region.
- Organism name Base comp Organism name Base comp. Mycobacterium avium A 16 G 32 C 18 T 16 Vibrio cholerae A 23 G 30 C 21 T 16 Streptomyces sp. A 17 G 38 C 27 T 14 A 23 G 31 C 21 T 15 Ureaplasma urealyticum A 18 G 30 C 17 T 17 A 23 G 31 C 21 T 15 Streptomyces sp.
- the same organism having different base compositions are different strains. Groups of organisms which are highlighted or in italics have the same base compositions in the amplified region. Some of these organisms can be distinguished using multiple primers. For example, Bacillus anthracis can be distinguished from Bacillus cereus and Bacillus thuringiensis using the primer 16S — 971-1062 (Table 6). Other primer pairs which produce unique base composition signatures are shown in Table 6 (bold). Clusters containing very similar threat and ubiquitous non-threat organisms (e.g. anthracis cluster) are distinguished at high resolution with focused sets of primer pairs.
- the known biowarfare agents in Table 6 are Bacillus anthracis, Yersinia pestis, Francisella tularensis and Rickettsia prowazekii .
- Organism 16S_971-1062 16S_1228-1310 16S_1100-1188 Aeromonas hydrophila A 21 G 29 C 22 T 20 A 22 G 27 C 21 T 13 A 23 G 31 C 21 T 15 Aeromonas salmonicida A 21 G 29 C 22 T 20 A 22 G 27 C 21 T 13 A 23 G 31 C 21 T 15
- Bacillus anthracis A 21 G 27 C 22 T 22 A 24 G 22 C 19 T 18 A 23 G 27 C 20 T 18
- Bacillus cereus A 22 G 27 C 21 T 22 A 24 G 22 C 19 T 18 A 23 G 27 C 20 T 18
- Bacillus thuringiensis A 22 G 27 C 21 T 22 A 24 G 22 C 19 T 18 A 23 G 27 C 20 T 18 Chlamydia trachomatis A 22 G 26 C
- B. anthracis has an ambiguous base at position 20.
- AACCCUAGAGAUAGGGCU (SEQ ID NO: 1) UCUCCUUCGGGAGCAGAGUGACAGGUGGUGCAUGGUU
- AACCCUAGAGAUAGGGCU (SEQ ID NO: 2) UCUCCUUCGGGAGCAGAGUGACAGGUGGUGCAUGGUU
- the mass measurement accuracy that can be obtained using an internal mass standard in the ESI-MS study of PCR products is shown in FIG. 8.
- the mass standard was a 20-mer phosphorothioate oligonucleotide added to a solution containing a 56-mer PCR product from the B. anthracis spore coat protein sspE.
- the mass of the expected PCR product distinguishes B. anthracis from other species of Bacillus such as B. thuringiensis and B. cereus.
- ESI-TOF MS spectra were obtained on a synthetic 56-mer oligonucleotide (5 ⁇ M)from the saspB gene of B. anthracis containing an internal mass standard at an ESI of 1.7 ⁇ L/min as a function of sample consumption.
- the results show that the signal to noise is improved as more scans are summed, and that the standard and the product are visible after only 100 scans.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/323,233 US20040121309A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues |
US10/326,051 US20040121313A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents in organs for transplantation |
US10/325,527 US20040121335A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections |
US10/325,526 US20040121311A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents in livestock |
US10/660,122 US7781162B2 (en) | 2001-03-02 | 2003-09-11 | Methods for rapid identification of pathogens in humans and animals |
AU2003297687A AU2003297687B2 (en) | 2001-03-02 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
JP2005508488A JP2006508696A (ja) | 2002-12-06 | 2003-12-05 | ヒトおよび動物における病原体の迅速な同定方法 |
PCT/US2003/038761 WO2004060278A2 (en) | 2002-12-06 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
EP03814656A EP1578399A4 (en) | 2002-12-06 | 2003-12-05 | METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND BEETS |
US10/728,486 US7718354B2 (en) | 2001-03-02 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
CA002508726A CA2508726A1 (en) | 2002-12-06 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
CA002508584A CA2508584A1 (en) | 2002-12-06 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
PCT/US2003/038830 WO2004052175A2 (en) | 2002-12-06 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
EP03796752A EP1581657A4 (en) | 2002-12-06 | 2003-12-05 | METHODS FOR THE RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND ANIMALS |
JP2005508560A JP2006516193A (ja) | 2002-12-06 | 2003-12-05 | ヒトおよび動物における病原体の迅速な同定方法 |
AU2003298030A AU2003298030B2 (en) | 2001-03-02 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
US11/869,449 US20080311558A1 (en) | 2001-03-02 | 2007-10-09 | Methods For Rapid Identification Of Pathogens In Humans And Animals |
US11/930,002 US8071309B2 (en) | 2002-12-06 | 2007-10-30 | Methods for rapid identification of pathogens in humans and animals |
US11/929,910 US8214154B2 (en) | 2001-03-02 | 2007-10-30 | Systems for rapid identification of pathogens in humans and animals |
AU2010200686A AU2010200686B2 (en) | 2001-03-02 | 2010-02-25 | Methods for rapid identification of pathogens in humans and animals |
US13/174,254 US9416424B2 (en) | 2001-03-02 | 2011-06-30 | Methods for rapid identification of pathogens in humans and animals |
US13/243,960 US8822156B2 (en) | 2002-12-06 | 2011-09-23 | Methods for rapid identification of pathogens in humans and animals |
US14/473,603 US9725771B2 (en) | 2002-12-06 | 2014-08-29 | Methods for rapid identification of pathogens in humans and animals |
US15/237,261 US20170044630A1 (en) | 2001-03-02 | 2016-08-15 | Methods For Rapid Identification Of Pathogens In Humans And Animals |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43131902P | 2002-12-06 | 2002-12-06 | |
US10/326,051 US20040121313A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents in organs for transplantation |
US10/323,233 US20040121309A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues |
US10/325,526 US20040121311A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents in livestock |
US10/325,527 US20040121335A1 (en) | 2002-12-06 | 2002-12-18 | Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections |
US44344303P | 2003-01-29 | 2003-01-29 | |
US44378803P | 2003-01-30 | 2003-01-30 | |
US44752903P | 2003-02-14 | 2003-02-14 | |
US10/660,122 US7781162B2 (en) | 2001-03-02 | 2003-09-11 | Methods for rapid identification of pathogens in humans and animals |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/326,051 Continuation-In-Part US20040121313A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents in organs for transplantation |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/660,122 Continuation-In-Part US7781162B2 (en) | 2001-03-02 | 2003-09-11 | Methods for rapid identification of pathogens in humans and animals |
US10/728,486 Continuation-In-Part US7718354B2 (en) | 2001-03-02 | 2003-12-05 | Methods for rapid identification of pathogens in humans and animals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040121309A1 true US20040121309A1 (en) | 2004-06-24 |
Family
ID=32512832
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/326,051 Abandoned US20040121313A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents in organs for transplantation |
US10/323,233 Abandoned US20040121309A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues |
US10/325,527 Abandoned US20040121335A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections |
US10/325,526 Abandoned US20040121311A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents in livestock |
US10/660,122 Expired - Fee Related US7781162B2 (en) | 2001-03-02 | 2003-09-11 | Methods for rapid identification of pathogens in humans and animals |
US11/869,449 Abandoned US20080311558A1 (en) | 2001-03-02 | 2007-10-09 | Methods For Rapid Identification Of Pathogens In Humans And Animals |
US11/929,910 Expired - Fee Related US8214154B2 (en) | 2001-03-02 | 2007-10-30 | Systems for rapid identification of pathogens in humans and animals |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/326,051 Abandoned US20040121313A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents in organs for transplantation |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/325,527 Abandoned US20040121335A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections |
US10/325,526 Abandoned US20040121311A1 (en) | 2001-03-02 | 2002-12-18 | Methods for rapid detection and identification of bioagents in livestock |
US10/660,122 Expired - Fee Related US7781162B2 (en) | 2001-03-02 | 2003-09-11 | Methods for rapid identification of pathogens in humans and animals |
US11/869,449 Abandoned US20080311558A1 (en) | 2001-03-02 | 2007-10-09 | Methods For Rapid Identification Of Pathogens In Humans And Animals |
US11/929,910 Expired - Fee Related US8214154B2 (en) | 2001-03-02 | 2007-10-30 | Systems for rapid identification of pathogens in humans and animals |
Country Status (5)
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040219517A1 (en) * | 2001-03-02 | 2004-11-04 | Ecker David J. | Methods for rapid identification of pathogens in humans and animals |
US20050270191A1 (en) * | 2004-05-24 | 2005-12-08 | Isis Pharmaceuticals, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US20070111234A1 (en) * | 2005-09-12 | 2007-05-17 | Christian Birkner | Detection of biological DNA |
US20080227087A1 (en) * | 2005-10-11 | 2008-09-18 | Ann Huletsky | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx |
US20090263809A1 (en) * | 2008-03-20 | 2009-10-22 | Zygem Corporation Limited | Methods for Identification of Bioagents |
US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US7666592B2 (en) | 2004-02-18 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US7718354B2 (en) | 2001-03-02 | 2010-05-18 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US7741036B2 (en) | 2001-03-02 | 2010-06-22 | Ibis Biosciences, Inc. | Method for rapid detection and identification of bioagents |
US7811753B2 (en) | 2004-07-14 | 2010-10-12 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
WO2011047307A1 (en) | 2009-10-15 | 2011-04-21 | Ibis Biosciences, Inc. | Multiple displacement amplification |
US7956175B2 (en) | 2003-09-11 | 2011-06-07 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
WO2011112718A1 (en) | 2010-03-10 | 2011-09-15 | Ibis Biosciences, Inc. | Production of single-stranded circular nucleic acid |
US8026084B2 (en) | 2005-07-21 | 2011-09-27 | Ibis Biosciences, Inc. | Methods for rapid identification and quantitation of nucleic acid variants |
US20110238316A1 (en) * | 2001-06-26 | 2011-09-29 | Ecker David J | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8046171B2 (en) | 2003-04-18 | 2011-10-25 | Ibis Biosciences, Inc. | Methods and apparatus for genetic evaluation |
US8057993B2 (en) | 2003-04-26 | 2011-11-15 | Ibis Biosciences, Inc. | Methods for identification of coronaviruses |
US8071309B2 (en) | 2002-12-06 | 2011-12-06 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8084207B2 (en) | 2005-03-03 | 2011-12-27 | Ibis Bioscience, Inc. | Compositions for use in identification of papillomavirus |
US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8119336B2 (en) | 2004-03-03 | 2012-02-21 | Ibis Biosciences, Inc. | Compositions for use in identification of alphaviruses |
US8148163B2 (en) | 2008-09-16 | 2012-04-03 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8158936B2 (en) | 2009-02-12 | 2012-04-17 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US8163895B2 (en) | 2003-12-05 | 2012-04-24 | Ibis Biosciences, Inc. | Compositions for use in identification of orthopoxviruses |
US8182992B2 (en) | 2005-03-03 | 2012-05-22 | Ibis Biosciences, Inc. | Compositions for use in identification of adventitious viruses |
US8298760B2 (en) | 2001-06-26 | 2012-10-30 | Ibis Bioscience, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
WO2013036603A1 (en) | 2011-09-06 | 2013-03-14 | Ibis Biosciences, Inc. | Sample preparation methods |
US8407010B2 (en) | 2004-05-25 | 2013-03-26 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA |
US8534447B2 (en) | 2008-09-16 | 2013-09-17 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8550694B2 (en) | 2008-09-16 | 2013-10-08 | Ibis Biosciences, Inc. | Mixing cartridges, mixing stations, and related kits, systems, and methods |
US8563250B2 (en) | 2001-03-02 | 2013-10-22 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
WO2014052590A1 (en) | 2012-09-26 | 2014-04-03 | Ibis Biosciences, Inc. | Swab interface for a microfluidic device |
US8871471B2 (en) | 2007-02-23 | 2014-10-28 | Ibis Biosciences, Inc. | Methods for rapid forensic DNA analysis |
US8950604B2 (en) | 2009-07-17 | 2015-02-10 | Ibis Biosciences, Inc. | Lift and mount apparatus |
US9068017B2 (en) | 2010-04-08 | 2015-06-30 | Ibis Biosciences, Inc. | Compositions and methods for inhibiting terminal transferase activity |
US9149473B2 (en) | 2006-09-14 | 2015-10-06 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
US9194877B2 (en) | 2009-07-17 | 2015-11-24 | Ibis Biosciences, Inc. | Systems for bioagent indentification |
US9393564B2 (en) | 2009-03-30 | 2016-07-19 | Ibis Biosciences, Inc. | Bioagent detection systems, devices, and methods |
US9416409B2 (en) | 2009-07-31 | 2016-08-16 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
US9777335B2 (en) | 2001-06-04 | 2017-10-03 | Geneohm Sciences Canada Inc. | Method for the detection and identification of methicillin-resistant Staphylococcus aureus |
US9970061B2 (en) | 2011-12-27 | 2018-05-15 | Ibis Biosciences, Inc. | Bioagent detection oligonucleotides |
US10584392B2 (en) | 2007-06-01 | 2020-03-10 | Council Of Scientific And Industrial Research | Method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2560521C (en) * | 2004-02-18 | 2012-01-03 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of bacteria |
CA2495138C (en) * | 2005-01-20 | 2012-10-23 | Alison Jane Basile | Multiplexed analysis for determining a serodiagnosis of viral infection |
DE602006017365D1 (de) * | 2005-04-13 | 2010-11-18 | Ibis Biosciences Inc | Zusammensetzungen für die identifizierung von adenoviren |
US20070026426A1 (en) | 2005-04-26 | 2007-02-01 | Applera Corporation | System for genetic surveillance and analysis |
CA2610836A1 (en) * | 2005-06-15 | 2006-12-28 | Gen-Probe Incorporated | Methods for quantitative analysis of a nucleic acid amplification reaction |
US7531309B2 (en) | 2005-12-06 | 2009-05-12 | Michigan State University | PCR based capsular typing method |
US7819615B2 (en) * | 2005-12-06 | 2010-10-26 | Hewlett-Packard Development | Method and apparatus for finishing sheets for a bound document |
EP2005348A4 (en) * | 2006-02-14 | 2011-11-09 | Intelliscience Corp | METHODS AND SYSTEMS FOR DATA ANALYSIS AND CHARACTERISTIC RECOGNITION COMPRISING DETECTION OF AVIAN INFLUENZA VIRUS |
US20070244844A1 (en) * | 2006-03-23 | 2007-10-18 | Intelliscience Corporation | Methods and systems for data analysis and feature recognition |
US8625885B2 (en) | 2006-03-23 | 2014-01-07 | Intelliscience Corporation | Methods and systems for data analysis and feature recognition |
EP2602321B1 (en) | 2006-05-31 | 2017-08-23 | Sequenom, Inc. | Methods and compositions for the extraction and amplification of nucleic acid from a sample |
WO2007147063A2 (en) * | 2006-06-16 | 2007-12-21 | Sequenom, Inc. | Methods and compositions for the amplification, detection and quantification of nucleic acid from a sample |
US7902345B2 (en) | 2006-12-05 | 2011-03-08 | Sequenom, Inc. | Detection and quantification of biomolecules using mass spectrometry |
US8076104B2 (en) * | 2007-01-25 | 2011-12-13 | Rogan Peter K | Rapid and comprehensive identification of prokaryotic organisms |
US8652780B2 (en) | 2007-03-26 | 2014-02-18 | Sequenom, Inc. | Restriction endonuclease enhanced polymorphic sequence detection |
US7811766B2 (en) * | 2007-03-28 | 2010-10-12 | Thinkvillage, Llc | Genetic identification and validation of Echinacea species |
EP1985712A1 (en) | 2007-04-17 | 2008-10-29 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Microbial population analysis |
US8527207B2 (en) * | 2007-05-15 | 2013-09-03 | Peter K. Rogan | Accurate identification of organisms based on individual information content |
US20090226895A1 (en) * | 2007-06-15 | 2009-09-10 | The Hong Kong Polytechnic University | Method of detecting vibrio parahaemolyticus via real-time PCR-hybridization |
ATE549419T1 (de) | 2007-08-29 | 2012-03-15 | Sequenom Inc | Verfahren und zusammensetzungen für die universelle grössenspezifische polymerasekettenreaktion |
EP2231851A4 (en) * | 2007-12-20 | 2011-02-02 | Biotrove Inc | SYSTEM FOR DETECTION OF BIOLOGICAL PATHOGEN AND USE THEREOF |
US9637776B2 (en) * | 2008-02-19 | 2017-05-02 | Opgen, Inc. | Methods of identifying an organism |
US8175992B2 (en) | 2008-03-17 | 2012-05-08 | Intelliscience Corporation | Methods and systems for compound feature creation, processing, and identification in conjunction with a data analysis and feature recognition system wherein hit weights are summed |
AU2009228312B2 (en) | 2008-03-26 | 2015-05-21 | Sequenom, Inc. | Restriction endonuclease enhanced polymorphic sequence detection |
WO2010080616A1 (en) | 2008-12-19 | 2010-07-15 | Abbott Laboratories | Molecular assay for diagnosis of malaria |
WO2010071821A1 (en) * | 2008-12-19 | 2010-06-24 | Abbott Laboratories | Diagnostic test for mutations in codons 12-13 of human k-ras |
EP2414545B1 (en) | 2009-04-03 | 2017-01-11 | Sequenom, Inc. | Nucleic acid preparation compositions and methods |
US9212397B2 (en) * | 2009-06-23 | 2015-12-15 | Gen-Probe Incorporated | Compositions and methods for detecting nucleic acid from mollicutes |
WO2011059802A1 (en) * | 2009-10-29 | 2011-05-19 | Bio-Rad Laboratories, Inc. | Rapid detection of mycoplasma contamination in cell culture samples |
EP2643460B1 (en) * | 2011-06-15 | 2017-07-26 | Grifols Therapeutics Inc. | Methods, compositions, and kits for determining human immunodeficiency virus (hiv) |
WO2014186874A1 (en) | 2013-05-23 | 2014-11-27 | Yyz Pharmatech, Inc. | Methods and compositions for enzyme linked immuno and hybridization mass spectrometric assay |
EP3351642B1 (en) | 2014-06-13 | 2019-09-11 | Q-Linea AB | Method for detecting and characterising a microorganism |
GB201507026D0 (en) | 2015-04-24 | 2015-06-10 | Linea Ab Q | Medical sample transportation container |
CA3011991A1 (en) * | 2016-01-21 | 2017-07-27 | T2 Biosystems, Inc. | Rapid antimicrobial susceptibility testing using high-sensitivity direct detection methods |
GB2554767A (en) | 2016-04-21 | 2018-04-11 | Q Linea Ab | Detecting and characterising a microorganism |
CN109423523A (zh) * | 2017-08-16 | 2019-03-05 | 台达电子工业股份有限公司 | 支原体检测方法及其试剂盒 |
WO2021247682A1 (en) * | 2020-06-02 | 2021-12-09 | Ross Peter M | Methods for mitigating or diminishing spread of pathogenic infections |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5502177A (en) * | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5622824A (en) * | 1993-03-19 | 1997-04-22 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US5645985A (en) * | 1991-11-26 | 1997-07-08 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5830653A (en) * | 1991-11-26 | 1998-11-03 | Gilead Sciences, Inc. | Methods of using oligomers containing modified pyrimidines |
US5849492A (en) * | 1994-02-28 | 1998-12-15 | Phylogenetix Laboratories, Inc. | Method for rapid identification of prokaryotic and eukaryotic organisms |
US5965363A (en) * | 1996-09-19 | 1999-10-12 | Genetrace Systems Inc. | Methods of preparing nucleic acids for mass spectrometric analysis |
US6007992A (en) * | 1997-11-10 | 1999-12-28 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US6028183A (en) * | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
Family Cites Families (401)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4075475A (en) | 1976-05-03 | 1978-02-21 | Chemetron Corporation | Programmed thermal degradation-mass spectrometry analysis method facilitating identification of a biological specimen |
US5688645A (en) | 1983-01-10 | 1997-11-18 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating non-viral organisms |
US5288611A (en) * | 1983-01-10 | 1994-02-22 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating organisms and viruses |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
WO1988003957A1 (en) | 1986-11-24 | 1988-06-02 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
KR960000479B1 (ko) | 1987-03-02 | 1996-01-08 | 젠-프로우브 인코오퍼레이티드 | 핵산 정제,분리 및 혼성체 형성용 다가양이온성 지지체 |
US5188963A (en) | 1989-11-17 | 1993-02-23 | Gene Tec Corporation | Device for processing biological specimens for analysis of nucleic acids |
US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
US5198543A (en) | 1989-03-24 | 1993-03-30 | Consejo Superior Investigaciones Cientificas | PHI29 DNA polymerase |
WO1990015157A1 (en) | 1989-05-31 | 1990-12-13 | Gene-Trak Systems | Universal eubacteria nucleic acid probes and methods |
US5219727A (en) | 1989-08-21 | 1993-06-15 | Hoffmann-Laroche Inc. | Quantitation of nucleic acids using the polymerase chain reaction |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5213961A (en) | 1989-08-31 | 1993-05-25 | Brigham And Women's Hospital | Accurate quantitation of RNA and DNA by competetitive polymerase chain reaction |
EP0667900B1 (en) | 1990-01-12 | 2001-05-23 | HSC Research Development Corporation | Introns and exons of the cystic fibrosis gene and mutations at various positions of the gene |
US5770029A (en) | 1996-07-30 | 1998-06-23 | Soane Biosciences | Integrated electrophoretic microdevices |
US5143905A (en) | 1990-05-03 | 1992-09-01 | The Regents Of The University Of California | Method and means for extending the host range of insecticidal proteins |
US5015845A (en) | 1990-06-01 | 1991-05-14 | Vestec Corporation | Electrospray method for mass spectrometry |
US5712125A (en) | 1990-07-24 | 1998-01-27 | Cemv Bioteknik Ab | Competitive PCR for quantitation of DNA |
DE4030262A1 (de) | 1990-09-25 | 1992-03-26 | Suedzucker Ag | Verfahren zur herstellung von rhamnose aus rhamnolipiden |
NL9002259A (nl) | 1990-10-17 | 1992-05-18 | Eurodiagnostics B V | Werkwijze voor het bepalen van een genotype door het vergelijken van de nucleotidensequentie van leden van een genfamilie, alsmede kit voor het opsporen van genetische variaties. |
WO1992009703A1 (en) | 1990-11-26 | 1992-06-11 | Cbr Laboratories, Inc. | Testing for spirochetal nucleic acid sequences in samples |
US5072115A (en) | 1990-12-14 | 1991-12-10 | Finnigan Corporation | Interpretation of mass spectra of multiply charged ions of mixtures |
WO1992013629A1 (en) | 1991-01-31 | 1992-08-20 | Wayne State University | A method for analyzing an organic sample |
IL97531A (en) * | 1991-03-12 | 1995-12-31 | Kelman Elliot | Hair cutting apparatus |
US5866429A (en) | 1991-04-03 | 1999-02-02 | Bloch; Will | Precision and accuracy of anion-exchange separation of nucleic acids |
US5472843A (en) | 1991-04-25 | 1995-12-05 | Gen-Probe Incorporated | Nucleic acid probes to Haemophilus influenzae |
US5213796A (en) | 1991-05-06 | 1993-05-25 | Dana Farber Cancer Institute | Assay for polyomavirus in humans and uses thereof |
US6055487A (en) | 1991-07-30 | 2000-04-25 | Margery; Keith S. | Interactive remote sample analysis system |
CA2116543C (en) | 1991-07-31 | 2007-10-02 | Kay S. Greisen | Methods and reagents for detection of bacteria in cerebrospinal fluid |
ES2214472T3 (es) | 1991-08-02 | 2004-09-16 | Biomerieux B.V. | Cuantificacion de acidos nucleicos. |
PT787807E (pt) | 1991-08-27 | 2003-08-29 | Hoffmann La Roche | Iniciadores e sondas para a deteccao da hepatite c |
AU2580892A (en) | 1991-09-05 | 1993-04-05 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
DE69231646T2 (de) | 1991-10-23 | 2001-06-13 | Baylor College Of Medicine, Houston | Fingerabdruckartige identifikation von bakterienstämmen mittels amplifikation repetitiver dna-sequenzen |
FR2683827B1 (fr) | 1991-11-15 | 1994-03-04 | Institut Nal Sante Recherc Medic | Procede de determination de la quantite d'un fragment d'adn d'interet par une methode d'amplification enzymatique. |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
IL103935A0 (en) | 1991-12-04 | 1993-05-13 | Du Pont | Method for the identification of microorganisms by the utilization of directed and arbitrary dna amplification |
AU3794893A (en) | 1992-03-13 | 1993-10-05 | Park Scientific Instruments Corp. | Scanning probe microscope |
US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
US6303297B1 (en) | 1992-07-17 | 2001-10-16 | Incyte Pharmaceuticals, Inc. | Database for storage and analysis of full-length sequences |
FR2694754B1 (fr) | 1992-08-12 | 1994-09-16 | Bio Merieux | Fragments d'ADN de mycobactéries, amorces d'amplification, sondes d'hybridation, réactifs et procédé de détection de détection de mycobactéries. |
AU5128593A (en) | 1992-09-16 | 1994-04-12 | University Of Tennessee Research Corporation, The | Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
AU5298393A (en) | 1992-10-08 | 1994-05-09 | Regents Of The University Of California, The | Pcr assays to determine the presence and concentration of a target |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US6436635B1 (en) | 1992-11-06 | 2002-08-20 | Boston University | Solid phase sequencing of double-stranded nucleic acids |
US6372424B1 (en) | 1995-08-30 | 2002-04-16 | Third Wave Technologies, Inc | Rapid detection and identification of pathogens |
US6194144B1 (en) | 1993-01-07 | 2001-02-27 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
FR2701961B1 (fr) | 1993-02-24 | 1995-04-21 | Bio Merieux | Procédé de destabilisation d'une structure secondaire intracaténaire d'un polynucléotide simple brin, et de capture dudit nucléotide. |
US6074823A (en) | 1993-03-19 | 2000-06-13 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US6323041B1 (en) * | 1993-06-11 | 2001-11-27 | Pfizer Inc. | Screening novel human phosphodiesterase IV isozymes for compounds which modify their enzymatic activity |
JPH0775585A (ja) | 1993-06-14 | 1995-03-20 | Immuno Japan:Kk | C型肝炎ウイルス関連オリゴヌクレオチドならびにc型肝炎 ウイルス遺伝子型判定方法 |
US5830853A (en) | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
US6001584A (en) | 1993-07-19 | 1999-12-14 | The Regents Of The University Of California | Oncoprotein protein kinase |
AU7551594A (en) | 1993-07-29 | 1995-02-28 | MURASHIGE, Kate H. | Method for recognition of the nucleotide sequence of a purified dna segment |
GB9315847D0 (en) | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
WO1995006752A1 (en) | 1993-09-03 | 1995-03-09 | Duke University | A method of nucleic acid sequencing |
US6376178B1 (en) | 1993-09-03 | 2002-04-23 | Duke University | Method of nucleic acid sequencing |
WO1995011996A1 (en) | 1993-10-27 | 1995-05-04 | Cornell Research Foundation, Inc. | Detection assay for listeria and erwinia microorganisms |
US5504327A (en) | 1993-11-04 | 1996-04-02 | Hv Ops, Inc. (H-Nu) | Electrospray ionization source and method for mass spectrometric analysis |
DE4338119A1 (de) | 1993-11-08 | 1995-05-11 | Bayer Ag | Spezifische Gensonden und Verfahren zum quantitativen Nachweis von methicillinresistenten Staphylococcen |
NL9301957A (nl) | 1993-11-11 | 1995-06-01 | U Gene Research Bv | Werkwijze voor het identificeren van micro-organismen, en daarvoor bruikbare hulpmiddelen. |
US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
JP3396942B2 (ja) | 1994-02-21 | 2003-04-14 | 三菱化学株式会社 | 芳香族ポリカーボネートの製造方法 |
US5608217A (en) | 1994-03-10 | 1997-03-04 | Bruker-Franzen Analytik Gmbh | Electrospraying method for mass spectrometric analysis |
DE4444229C2 (de) | 1994-03-10 | 1996-07-25 | Bruker Franzen Analytik Gmbh | Verfahren und Vorrichtungen zur Elektrosprüh-Ionisierung für speichernde Massenspektometer |
US5976798A (en) | 1994-03-30 | 1999-11-02 | Mitokor | Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid |
WO1995031997A1 (en) | 1994-05-20 | 1995-11-30 | UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY | Model for testing immunogenicity of peptides |
US5814442A (en) | 1994-06-10 | 1998-09-29 | Georgetown University | Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid |
DE4421901A1 (de) | 1994-06-23 | 1996-01-04 | Bayer Ag | Ein DNA-Schnelltest zum Nachweis von chinolonresistenten Staphylococcus aureus Erregern in klinischem Probenmaterial |
GB9417211D0 (en) | 1994-08-25 | 1994-10-12 | Solicitor For The Affairs Of H | Nucleotide sequencing method |
US20020055101A1 (en) | 1995-09-11 | 2002-05-09 | Michel G. Bergeron | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
US6001564A (en) | 1994-09-12 | 1999-12-14 | Infectio Diagnostic, Inc. | Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
CA2118048C (en) | 1994-09-30 | 2003-04-08 | James W. Schumm | Multiplex amplification of short tandem repeat loci |
US5753489A (en) | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
US5654141A (en) | 1994-11-18 | 1997-08-05 | Thomas Jefferson University | Amplification based detection of bacterial infection |
KR100399813B1 (ko) | 1994-12-14 | 2004-06-09 | 가부시키가이샤 니콘 | 노광장치 |
US5763169A (en) | 1995-01-13 | 1998-06-09 | Chiron Diagnostics Corporation | Nucleic acid probes for the detection and identification of fungi |
US5707802A (en) | 1995-01-13 | 1998-01-13 | Ciba Corning Diagnostics Corp. | Nucleic acid probes for the detection and identification of fungi |
US6180339B1 (en) | 1995-01-13 | 2001-01-30 | Bayer Corporation | Nucleic acid probes for the detection and identification of fungi |
US5702895A (en) | 1995-01-19 | 1997-12-30 | Wakunaga Seiyaku Kabushiki Kaisha | Method and kit for detecting methicillin-resistant Staphylococcus aureus |
US5484808A (en) * | 1995-02-09 | 1996-01-16 | Eli Lilly And Company | Methods of inhibiting cell-cell adhesion |
GB9504598D0 (en) | 1995-03-03 | 1995-04-26 | Imp Cancer Res Tech | Method of nucleic acid analysis |
US6428955B1 (en) | 1995-03-17 | 2002-08-06 | Sequenom, Inc. | DNA diagnostics based on mass spectrometry |
EP0830460A1 (en) | 1995-04-11 | 1998-03-25 | Trustees Of Boston University | Solid phase sequencing of biopolymers |
TW399094B (en) * | 1995-04-11 | 2000-07-21 | Ciba Sc Holding Ag | Compounds with (benzo)triazole radicals |
US5932220A (en) | 1995-05-08 | 1999-08-03 | Board Of Regents University Of Texas System | Diagnostic tests for a new spirochete, Borrelia lonestari sp. nov. |
US5625184A (en) | 1995-05-19 | 1997-04-29 | Perseptive Biosystems, Inc. | Time-of-flight mass spectrometry analysis of biomolecules |
US5830655A (en) | 1995-05-22 | 1998-11-03 | Sri International | Oligonucleotide sizing using cleavable primers |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
AU708995B2 (en) | 1995-06-07 | 1999-08-19 | Gene Shears Pty. Limited | Optimized minizymes and miniribozymes and uses thereof |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
US6146854A (en) * | 1995-08-31 | 2000-11-14 | Sequenom, Inc. | Filtration processes, kits and devices for isolating plasmids |
US5994066A (en) | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
US5869242A (en) | 1995-09-18 | 1999-02-09 | Myriad Genetics, Inc. | Mass spectrometry to assess DNA sequence polymorphisms |
US5727202A (en) | 1995-10-18 | 1998-03-10 | Palm Computing, Inc. | Method and apparatus for synchronizing information on two different computer systems |
US5972693A (en) | 1995-10-24 | 1999-10-26 | Curagen Corporation | Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
US5871697A (en) | 1995-10-24 | 1999-02-16 | Curagen Corporation | Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
US5716825A (en) | 1995-11-01 | 1998-02-10 | Hewlett Packard Company | Integrated nucleic acid analysis system for MALDI-TOF MS |
US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
GB9602028D0 (en) | 1996-02-01 | 1996-04-03 | Amersham Int Plc | Nucleoside analogues |
US6852487B1 (en) | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP0886681A1 (en) | 1996-03-04 | 1998-12-30 | Genetrace Systems, Inc. | Methods of screening nucleic acids using mass spectrometry |
AU2217597A (en) | 1996-03-18 | 1997-10-22 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
CA2222192A1 (fr) | 1996-03-20 | 1997-09-25 | Bio Merieux | Isolement de l'acide nucleique |
JP3365198B2 (ja) | 1996-03-21 | 2003-01-08 | ミノルタ株式会社 | 画像形成装置 |
US5745751A (en) | 1996-04-12 | 1998-04-28 | Nelson; Robert W. | Civil site information system |
US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
EP0954611A1 (en) | 1996-06-10 | 1999-11-10 | University Of Utah Research Foundation | Rapid, accurate identification of dna sequence variants by electrospray mass spectrometry |
WO1998003684A1 (en) | 1996-07-19 | 1998-01-29 | Hybridon, Inc. | Method for sequencing nucleic acids using matrix-assisted laser desorption ionization time-of-flight mass spectrometry |
US6563025B1 (en) | 1996-07-26 | 2003-05-13 | Board Of Trustees Of The University Of Illinois | Nucleotide sequences encoding anthranilate synthase |
US5831046A (en) * | 1996-08-05 | 1998-11-03 | Prolinx, Incorporated | Boronic acid-contaning nucleic acid monomers |
DE19633436A1 (de) | 1996-08-20 | 1998-02-26 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Nukleinsäuren unter Ermittlung der Masse |
CA2301875A1 (en) | 1996-09-19 | 1998-03-26 | Genetrace Systems | Methods of preparing nucleic acids for mass spectrometric analysis |
US5777324A (en) | 1996-09-19 | 1998-07-07 | Sequenom, Inc. | Method and apparatus for maldi analysis |
US6361940B1 (en) | 1996-09-24 | 2002-03-26 | Qiagen Genomics, Inc. | Compositions and methods for enhancing hybridization and priming specificity |
US5864137A (en) | 1996-10-01 | 1999-01-26 | Genetrace Systems, Inc. | Mass spectrometer |
US5885775A (en) | 1996-10-04 | 1999-03-23 | Perseptive Biosystems, Inc. | Methods for determining sequences information in polynucleotides using mass spectrometry |
GB9620769D0 (en) | 1996-10-04 | 1996-11-20 | Brax Genomics Ltd | Nucleic acid sequencing |
US6110710A (en) | 1996-10-15 | 2000-08-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Sequence modification of oligonucleotide primers to manipulate non-templated nucleotide addition |
US7285422B1 (en) | 1997-01-23 | 2007-10-23 | Sequenom, Inc. | Systems and methods for preparing and analyzing low volume analyte array elements |
US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US20030129589A1 (en) | 1996-11-06 | 2003-07-10 | Hubert Koster | Dna diagnostics based on mass spectrometry |
US6133436A (en) | 1996-11-06 | 2000-10-17 | Sequenom, Inc. | Beads bound to a solid support and to nucleic acids |
US6024925A (en) | 1997-01-23 | 2000-02-15 | Sequenom, Inc. | Systems and methods for preparing low volume analyte array elements |
US5900481A (en) | 1996-11-06 | 1999-05-04 | Sequenom, Inc. | Bead linkers for immobilizing nucleic acids to solid supports |
EP1457496B1 (en) | 1996-11-06 | 2014-01-15 | Sequenom, Inc. | High density immobilization of nucleic acids |
US6060246A (en) | 1996-11-15 | 2000-05-09 | Avi Biopharma, Inc. | Reagent and method for isolation and detection of selected nucleic acid sequences |
KR20000057275A (ko) * | 1996-11-28 | 2000-09-15 | 후지타 기요시 | 당 화합물, 겔화제, 겔화제 조성물, 이들의 제조 방법 및 겔상조성물 |
US5822824A (en) | 1996-12-03 | 1998-10-20 | Dion; William D. | Mountable washing device |
AU5794498A (en) | 1996-12-10 | 1998-07-03 | Genetrace Systems, Inc. | Releasable nonvolatile mass-label molecules |
US5981190A (en) | 1997-01-08 | 1999-11-09 | Ontogeny, Inc. | Analysis of gene expression, methods and reagents therefor |
US5876936A (en) | 1997-01-15 | 1999-03-02 | Incyte Pharmaceuticals, Inc. | Nucleic acid sequencing with solid phase capturable terminators |
ATE340869T1 (de) | 1997-01-15 | 2006-10-15 | Xzillion Gmbh & Co Kg | Massenmarkierte hybridisierungssonden |
US6046005A (en) | 1997-01-15 | 2000-04-04 | Incyte Pharmaceuticals, Inc. | Nucleic acid sequencing with solid phase capturable terminators comprising a cleavable linking group |
WO1998035057A1 (en) | 1997-02-06 | 1998-08-13 | The National University Of Singapore | Diagnosis of plasmodium infection by analysis of extrachromosomal genetic material |
US6727061B2 (en) | 1997-02-20 | 2004-04-27 | Cabtec, Inc. | Methods for identifying species or Shigella and E. coli using operon sequence analysis |
US5828062A (en) | 1997-03-03 | 1998-10-27 | Waters Investments Limited | Ionization electrospray apparatus for mass spectrometry |
US6553317B1 (en) | 1997-03-05 | 2003-04-22 | Incyte Pharmaceuticals, Inc. | Relational database and system for storing information relating to biomolecular sequences and reagents |
DE19710166C1 (de) | 1997-03-12 | 1998-12-10 | Bruker Franzen Analytik Gmbh | Zwei-Schritt-Verfahren der DNA-Amplifikation für MALDI-TOF-Messungen |
AU6553498A (en) | 1997-03-14 | 1998-09-29 | Hybridon, Inc. | Method for sequencing of modified nucleic acids using electrospray ionization-fourier transform mass spectrometry |
US5849497A (en) | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
US6018713A (en) | 1997-04-09 | 2000-01-25 | Coli; Robert D. | Integrated system and method for ordering and cumulative results reporting of medical tests |
DE19717085C2 (de) | 1997-04-23 | 1999-06-17 | Bruker Daltonik Gmbh | Verfahren und Geräte für extrem schnelle DNA-Vervielfachung durch Polymerase-Kettenreaktionen (PCR) |
US20010039263A1 (en) | 1997-05-02 | 2001-11-08 | Max-Delbruck-Centrum Fur Molekulare Medizin | Chimeric oligonucleotides and the use thereof |
US6054278A (en) * | 1997-05-05 | 2000-04-25 | The Perkin-Elmer Corporation | Ribosomal RNA gene polymorphism based microorganism identification |
US6994960B1 (en) | 1997-05-28 | 2006-02-07 | The Walter And Eliza Hall Institute Of Medical Research | Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage |
US6159681A (en) | 1997-05-28 | 2000-12-12 | Syntrix Biochip, Inc. | Light-mediated method and apparatus for the regional analysis of biologic material |
WO1998054751A1 (en) | 1997-05-30 | 1998-12-03 | Genetrace Systems, Inc. | Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry |
US6061686A (en) | 1997-06-26 | 2000-05-09 | Digital Equipment Corporation | Updating a copy of a remote document stored in a local computer system |
NZ501919A (en) | 1997-07-22 | 2001-11-30 | Qiagen Genomics Inc | Methods for analyzing nucleic acid molecules utilizing mass spectroscopy readable tags |
DE19732086C2 (de) | 1997-07-25 | 2002-11-21 | Univ Leipzig | Verfahren zur quantitativen Bestimmung von Eubakterien |
US6207370B1 (en) | 1997-09-02 | 2001-03-27 | Sequenom, Inc. | Diagnostics based on mass spectrometric detection of translated target polypeptides |
GB9719044D0 (en) | 1997-09-08 | 1997-11-12 | Inst Of Ophthalmology | Assay |
US6090558A (en) | 1997-09-19 | 2000-07-18 | Genetrace Systems, Inc. | DNA typing by mass spectrometry with polymorphic DNA repeat markers |
US6063031A (en) | 1997-10-14 | 2000-05-16 | Assurance Medical, Inc. | Diagnosis and treatment of tissue with instruments |
US6111096A (en) | 1997-10-31 | 2000-08-29 | Bbi Bioseq, Inc. | Nucleic acid isolation and purification |
JP3423597B2 (ja) | 1997-11-05 | 2003-07-07 | 三井農林株式会社 | 細菌の同定方法 |
WO1999029898A2 (de) | 1997-12-05 | 1999-06-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur identifikation von nucleinsäuren durch matrix-assistierte laser desorptions/ionisations massenspektrometrie |
US6914137B2 (en) | 1997-12-06 | 2005-07-05 | Dna Research Innovations Limited | Isolation of nucleic acids |
US6268131B1 (en) | 1997-12-15 | 2001-07-31 | Sequenom, Inc. | Mass spectrometric methods for sequencing nucleic acids |
GB9815166D0 (en) | 1998-07-13 | 1998-09-09 | Brax Genomics Ltd | Compounds for mass spectrometry |
US6458533B1 (en) | 1997-12-19 | 2002-10-01 | High Throughput Genomics, Inc. | High throughput assay system for monitoring ESTs |
US20030096232A1 (en) | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
DE19802905C2 (de) | 1998-01-27 | 2001-11-08 | Bruker Daltonik Gmbh | Verfahren zur bevorzugten Herstellung nur eines Stranges selektierten Genmaterials für massenspektrometrische Messungen |
US6428956B1 (en) | 1998-03-02 | 2002-08-06 | Isis Pharmaceuticals, Inc. | Mass spectrometric methods for biomolecular screening |
WO1999046047A2 (en) | 1998-03-10 | 1999-09-16 | Large Scale Proteomics Corporation | Detection and characterization of microorganisms |
US6391551B1 (en) | 1998-03-13 | 2002-05-21 | Promega Corporation | Detection of nucleic acid hybrids |
US6235480B1 (en) | 1998-03-13 | 2001-05-22 | Promega Corporation | Detection of nucleic acid hybrids |
US6270973B1 (en) | 1998-03-13 | 2001-08-07 | Promega Corporation | Multiplex method for nucleic acid detection |
US6268146B1 (en) | 1998-03-13 | 2001-07-31 | Promega Corporation | Analytical methods and materials for nucleic acid detection |
US6312902B1 (en) | 1998-03-13 | 2001-11-06 | Promega Corporation | Nucleic acid detection |
US6277578B1 (en) | 1998-03-13 | 2001-08-21 | Promega Corporation | Deploymerization method for nucleic acid detection of an amplified nucleic acid target |
US6270974B1 (en) | 1998-03-13 | 2001-08-07 | Promega Corporation | Exogenous nucleic acid detection |
US6261769B1 (en) | 1998-03-31 | 2001-07-17 | The United States Of America As Represented By The Secretary Of Agriculture | Intergenic spacer target sequence for detecting and distinguishing Chlamydial species or strains |
US7321828B2 (en) | 1998-04-13 | 2008-01-22 | Isis Pharmaceuticals, Inc. | System of components for preparing oligonucleotides |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US6223186B1 (en) | 1998-05-04 | 2001-04-24 | Incyte Pharmaceuticals, Inc. | System and method for a precompiled database for biomolecular sequence information |
US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
DE19822108A1 (de) | 1998-05-12 | 2000-02-03 | Schering Ag | Verfahren zur Detektion von Mikroorganismen in Produkten, insbesondere in Arzneimitteln und Kosmetika |
US6221587B1 (en) | 1998-05-12 | 2001-04-24 | Isis Pharmceuticals, Inc. | Identification of molecular interaction sites in RNA for novel drug discovery |
DE19922161A1 (de) | 1998-05-18 | 1999-12-09 | Fraunhofer Ges Forschung | Anti-Haft-Beschichtung und Verfahren zu ihrer Herstellung |
US6468743B1 (en) | 1998-05-18 | 2002-10-22 | Conagra Grocery Products Company | PCR techniques for detecting microbial contaminants in foodstuffs |
US6104028A (en) | 1998-05-29 | 2000-08-15 | Genetrace Systems Inc. | Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry |
DE19824280B4 (de) | 1998-05-29 | 2004-08-19 | Bruker Daltonik Gmbh | Mutationsanalyse mittels Massenspektrometrie |
GB2339905A (en) | 1998-06-24 | 2000-02-09 | Bruker Daltonik Gmbh | Use of mass-specrometry for detection of mutations |
DE69941333D1 (de) | 1998-07-02 | 2009-10-08 | Gen Probe Inc | Molekulare fackeln |
US6218118B1 (en) | 1998-07-09 | 2001-04-17 | Agilent Technologies, Inc. | Method and mixture reagents for analyzing the nucleotide sequence of nucleic acids by mass spectrometry |
US6074831A (en) | 1998-07-09 | 2000-06-13 | Agilent Technologies, Inc. | Partitioning of polymorphic DNAs |
US6432651B1 (en) | 1998-07-10 | 2002-08-13 | Cetek Corporation | Method to detect and analyze tight-binding ligands in complex biological samples using capillary electrophoresis and mass spectrometry |
US6605433B1 (en) | 1998-08-20 | 2003-08-12 | The Johns Hopkins University | Mitochondrial dosimeter |
US6146144A (en) | 1998-09-29 | 2000-11-14 | Fowler; Ernest R. | Rug hooking kit and method for handicapped |
US6610492B1 (en) | 1998-10-01 | 2003-08-26 | Variagenics, Inc. | Base-modified nucleotides and cleavage of polynucleotides incorporating them |
US6238927B1 (en) | 1998-10-05 | 2001-05-29 | Mosaic Technologies, Incorporated | Reverse displacement assay for detection of nucleic acid sequences |
DE19852167C2 (de) | 1998-11-12 | 2000-12-14 | Bruker Saxonia Analytik Gmbh | Einfache SNP-Analyse mittels Massenspektrometrie |
EP1144594A1 (en) | 1998-11-24 | 2001-10-17 | Regents Of The University Of Minnesota | Transgenic circulating endothelial cells |
US6994962B1 (en) | 1998-12-09 | 2006-02-07 | Massachusetts Institute Of Technology | Methods of identifying point mutations in a genome |
DE19859723A1 (de) | 1998-12-23 | 2000-06-29 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
US7432049B2 (en) | 2001-02-28 | 2008-10-07 | Chondrogene Limited | Compositions and methods relating to osteoarthritis |
US6503718B2 (en) | 1999-01-10 | 2003-01-07 | Exact Sciences Corporation | Methods for detecting mutations using primer extension for detecting disease |
US6638714B1 (en) | 1999-02-03 | 2003-10-28 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof |
US6153389A (en) | 1999-02-22 | 2000-11-28 | Haarer; Brian K. | DNA additives as a mechanism for unambiguously marking biological samples |
EP1035219A1 (en) | 1999-02-25 | 2000-09-13 | Universiteit Gent | Gastric helicobacter 16 S rDNA sequences from cattle and pigs and their use for detection and typing of Helicobacter strains |
DE19910592A1 (de) * | 1999-03-10 | 2000-09-14 | Volkswagen Ag | Rückhaltevorrichtung |
US6436640B1 (en) | 1999-03-18 | 2002-08-20 | Exiqon A/S | Use of LNA in mass spectrometry |
US6613509B1 (en) | 1999-03-22 | 2003-09-02 | Regents Of The University Of California | Determination of base (nucleotide) composition in DNA oligomers by mass spectrometry |
EP1171584A1 (en) | 1999-04-21 | 2002-01-16 | Annovis, Inc. | Magnetic dna extraction kit for plants |
US6140067A (en) | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
US6649351B2 (en) | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
AU778230B2 (en) | 1999-05-03 | 2004-11-25 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
US20020086289A1 (en) | 1999-06-15 | 2002-07-04 | Don Straus | Genomic profiling: a rapid method for testing a complex biological sample for the presence of many types of organisms |
MXPA02000192A (es) | 1999-06-30 | 2004-08-12 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de pulmon. |
AU5371099A (en) | 1999-07-22 | 2001-02-13 | Artus Gesellschaft Fur Molekularbiologische Diagnostik Und Entwicklung Mbh | Method for the species-specific detection of organisms |
US6723505B1 (en) | 1999-08-13 | 2004-04-20 | Nye Colifast As | Method for identification of the indicators of contamination in liquid samples |
US6266144B1 (en) | 1999-08-26 | 2001-07-24 | Taiwan Semiconductor Manufacturing Company | Stepper and scanner new exposure sequence with intra-field correction |
DE19943374A1 (de) | 1999-09-10 | 2001-03-29 | Max Planck Gesellschaft | Verfahren zum Anbinden von Nukleinsäuren an eine Festphase |
US7005274B1 (en) | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
WO2001023608A2 (en) | 1999-09-27 | 2001-04-05 | Merck Sharp & Dohme De Espana, S.A.E. | Hybridization probes which specifically detect strains of the genera microbispora, microtetraspora, nonomuria and planobispora |
EP2322666A3 (en) | 1999-09-28 | 2011-08-10 | Geneohm Sciences Canada, Inc. | Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms. |
US6296188B1 (en) | 1999-10-01 | 2001-10-02 | Perfect Plastic Printing Corporation | Transparent/translucent financial transaction card including an infrared light filter |
US6787302B2 (en) | 1999-10-25 | 2004-09-07 | Genprime, Inc. | Method and apparatus for prokaryotic and eukaryotic cell quantitation |
WO2001032930A1 (en) | 1999-11-04 | 2001-05-10 | California Institute Of Technology | Methods and apparatuses for analyzing polynucleotide sequences |
US6856914B1 (en) | 1999-11-19 | 2005-02-15 | The University Of British Columbia | Method, apparatus, media and signals for identifying associated cell signaling proteins |
KR20020060242A (ko) | 1999-11-29 | 2002-07-16 | 추후제출 | 환경 샘플로부터 핵산의 수득방법, 수득된 핵산 및 신규화합물 합성에서의 이의 용도 |
US6608190B1 (en) * | 1999-12-16 | 2003-08-19 | E. I. Du Pont De Nemours And Company | Nucleic acid fragments for the identification of bacteria in industrial wastewater bioreactors |
US6936414B2 (en) | 1999-12-22 | 2005-08-30 | Abbott Laboratories | Nucleic acid isolation method and kit |
US7166429B2 (en) | 1999-12-29 | 2007-01-23 | Keygene N.V. | Method for generating oligonucleotides, in particular for the detection of amplified restriction fragments obtained using AFLP® |
SE0000061D0 (sv) | 2000-01-10 | 2000-01-10 | Bjoern Herrmann | A method for detection of pathogenic organisms |
AU2001232485A1 (en) | 2000-01-13 | 2001-07-24 | Amsterdam Support Diagnostics B.V. | A universal nucleic acid amplification system for nucleic acids in a sample |
US20020009727A1 (en) | 2000-02-02 | 2002-01-24 | Schultz Gary A. | Detection of single nucleotide polymorphisms |
CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
US6453244B1 (en) | 2000-02-10 | 2002-09-17 | Stanford University | Detection of polymorphisms by denaturing high-performance liquid chromatography |
US6569093B2 (en) | 2000-02-14 | 2003-05-27 | First Opinion Corporation | Automated diagnostic system and method including disease timeline |
US6393367B1 (en) | 2000-02-19 | 2002-05-21 | Proteometrics, Llc | Method for evaluating the quality of comparisons between experimental and theoretical mass data |
DE10015797B4 (de) | 2000-03-26 | 2006-02-02 | Bruker Daltonik Gmbh | Multiplex-Analyse von DNA-Gemischen mittels photolytisch ablesbarer DNA-Chips |
DE10015262A1 (de) | 2000-03-28 | 2001-10-04 | Basf Ag | Papierstreichmassen, enthaltend Bindemittel mit Makromonomeren |
AU6052001A (en) | 2000-03-29 | 2001-10-08 | Ct For The Applic Of Molecular | Methods for genotyping by hybridization analysis |
DK2278029T3 (en) | 2000-04-10 | 2016-10-03 | Taxon Biosciences Inc | Methods of study and genetic analysis of populations |
US6475736B1 (en) | 2000-05-23 | 2002-11-05 | Variagenics, Inc. | Methods for genetic analysis of DNA using biased amplification of polymorphic sites |
US6716634B1 (en) | 2000-05-31 | 2004-04-06 | Agilent Technologies, Inc. | Increasing ionization efficiency in mass spectrometry |
US6507837B1 (en) | 2000-06-08 | 2003-01-14 | Hyperphrase Technologies, Llc | Tiered and content based database searching |
CA2412223A1 (en) | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
AU2001268468A1 (en) | 2000-06-13 | 2001-12-24 | The Trustees Of Boston University | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing |
EP1170379A1 (en) * | 2000-06-30 | 2002-01-09 | Centre National de Genotypage | Sample generation for genotyping by mass spectrometry |
FR2811321A1 (fr) | 2000-07-04 | 2002-01-11 | Bio Merieux | Amplificateur d'une region ribonucleique cible d'un arn ribosomal 16s ou adn pour un tel arn d'une espece eubacterienne et detection de telles especes |
US6504021B2 (en) | 2000-07-05 | 2003-01-07 | Edge Biosystems, Inc. | Ion exchange method for DNA purification |
WO2002002811A2 (fr) | 2000-07-06 | 2002-01-10 | Bio Merieux | Procede de controle de la qualite microbiologique d'un milieu aqueux et necessaire approprie |
US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
WO2002010186A1 (en) | 2000-07-27 | 2002-02-07 | California Institute Of Technology | A rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping |
AUPQ909000A0 (en) | 2000-07-28 | 2000-08-24 | University Of Sydney, The | A method of detecting microorganisms |
US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US20040005555A1 (en) * | 2000-08-31 | 2004-01-08 | Rothman Richard E. | Molecular diagnosis of bactermia |
US7349808B1 (en) | 2000-09-06 | 2008-03-25 | Egenomics, Inc. | System and method for tracking and controlling infections |
US20020120408A1 (en) | 2000-09-06 | 2002-08-29 | Kreiswirth Barry N. | System and method for tracking and controlling infections |
US6813615B1 (en) | 2000-09-06 | 2004-11-02 | Cellomics, Inc. | Method and system for interpreting and validating experimental data with automated reasoning |
AU2001288762A1 (en) | 2000-09-08 | 2002-03-22 | Large Scale Proteomics Corporation | Detection and characterization of microorganisms |
SE0003286D0 (sv) | 2000-09-15 | 2000-09-15 | Ulf Gyllensten | Method and kit for human identification |
ES2327103T3 (es) | 2000-09-25 | 2009-10-26 | Polymun Scientific Immunbiologische Forschung Gmbh | Vacuna viva de influenzavirus y procedimiento de fabricacion. |
WO2002028901A2 (en) | 2000-10-05 | 2002-04-11 | Millennium Pharmaceuticals, Inc. | Seven-transmembrane (7tm) receptors and uses thereof |
US6996472B2 (en) | 2000-10-10 | 2006-02-07 | The United States Of America As Represented By The Department Of Health And Human Services | Drift compensation method for fingerprint spectra |
AU2002213345A1 (en) | 2000-10-13 | 2002-04-22 | Irm, Llc | High throughput processing system and method of using |
ATE380883T1 (de) | 2000-10-24 | 2007-12-15 | Univ Leland Stanford Junior | Direkte multiplex charakterisierung von genomischer dna |
US6906316B2 (en) | 2000-10-27 | 2005-06-14 | Fuji Electric Co., Ltd. | Semiconductor device module |
US6682889B1 (en) | 2000-11-08 | 2004-01-27 | Becton, Dickinson And Company | Amplification and detection of organisms of the Chlamydiaceae family |
AU2002222614A1 (en) | 2000-12-12 | 2002-07-01 | Chugai Seiyaku Kabushiki Kaisha | Method of detecting polymorphism in dna by using mass spectroscopy |
US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
US6586584B2 (en) | 2001-01-29 | 2003-07-01 | Becton, Dickinson And Company | Sequences and methods for detection of Hepatitis C virus |
DE10108453B4 (de) | 2001-02-22 | 2005-10-20 | Bruker Daltonik Gmbh | Massenspektrometrische Mutationsanalyse mit photolytisch spaltbaren Primern |
US6699670B2 (en) | 2001-03-01 | 2004-03-02 | The Johns Hopkins University | Quantitative assay for the simultaneous detection and speciation of bacterial infections |
US20040121313A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in organs for transplantation |
US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US20040121310A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in forensic studies |
US20030027135A1 (en) | 2001-03-02 | 2003-02-06 | Ecker David J. | Method for rapid detection and identification of bioagents |
US7226739B2 (en) * | 2001-03-02 | 2007-06-05 | Isis Pharmaceuticals, Inc | Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations |
US7718354B2 (en) | 2001-03-02 | 2010-05-18 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US20040121314A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in containers |
US20040038206A1 (en) | 2001-03-14 | 2004-02-26 | Jia Zhang | Method for high throughput assay of genetic analysis |
US20030104410A1 (en) | 2001-03-16 | 2003-06-05 | Affymetrix, Inc. | Human microarray |
ATE335754T1 (de) | 2001-03-19 | 2006-09-15 | Harvard College | Entwicklung neuer molekularer funktionen |
JP4927309B2 (ja) | 2001-03-28 | 2012-05-09 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | 野生生物同定のための普遍的プライマー |
US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
CA2348042A1 (en) | 2001-06-04 | 2002-12-04 | Ann Huletsky | Sequences for detection and identification of methicillin-resistant staphylococcus aureus |
US20020187477A1 (en) | 2001-06-06 | 2002-12-12 | Hong Xue | Method for detecting single nucleotide polymorphisms (SNPs) and point mutations |
ES2311613T3 (es) | 2001-06-06 | 2009-02-16 | Dsm Ip Assets B.V. | Produccion mejorada de isoprenoides. |
GB0113908D0 (en) | 2001-06-07 | 2001-08-01 | Univ London | Designing degenerate PCR primers |
US20020187490A1 (en) | 2001-06-07 | 2002-12-12 | Michigan State University | Microbial identification chip based on DNA-DNA hybridization |
GB0113907D0 (en) | 2001-06-07 | 2001-08-01 | Univ London | Virus detection using degenerate PCR primers |
US7217510B2 (en) | 2001-06-26 | 2007-05-15 | Isis Pharmaceuticals, Inc. | Methods for providing bacterial bioagent characterizing information |
US8073627B2 (en) | 2001-06-26 | 2011-12-06 | Ibis Biosciences, Inc. | System for indentification of pathogens |
DE10132147B4 (de) | 2001-07-03 | 2004-04-15 | Universität Leipzig | Verfahren zur schnellen quantitativen Bestimmung von Eu-Bakterien |
GB0117054D0 (en) | 2001-07-12 | 2001-09-05 | Plant Bioscience Ltd | Methods and means for modification of plant characteristics |
EP1407051B1 (en) | 2001-07-19 | 2006-04-12 | Infectio Diagnostic (I.D.I.) INC. | Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their detection |
US20040191769A1 (en) | 2001-07-24 | 2004-09-30 | Transgenomic, Inc. | Methods, compositions, and kits for mutation detection in mitochondrial DNA |
AU2002325197A1 (en) | 2001-07-30 | 2003-02-17 | Den Kgl. Veterinaer- Og Landbohojskole | Bacterial strains belonging to lactobacillus species and their use in food and feed industry |
US7115385B2 (en) | 2001-08-02 | 2006-10-03 | North Carolina State University | Media and methods for cultivation of microorganisms |
AT411174B (de) | 2001-08-09 | 2003-10-27 | Lambda Labor Fuer Molekularbio | Verfahren und chip zur analyse von nukleinsäuren |
US20030039976A1 (en) | 2001-08-14 | 2003-02-27 | Haff Lawrence A. | Methods for base counting |
US20040175715A1 (en) | 2001-08-21 | 2004-09-09 | Burgoyne Leigh A. | Method and device for simultaneously molecularly cloning and polylocus profiling of genomes or genomes mixtures |
US7105296B2 (en) | 2001-08-29 | 2006-09-12 | E. I. Du Pont De Nemours And Company | Genes encoding Baeyer-Villiger monooxygenases |
US7049286B2 (en) | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
US7060809B2 (en) | 2001-09-04 | 2006-06-13 | Exiqon A/S | LNA compositions and uses thereof |
US20040101809A1 (en) | 2001-09-21 | 2004-05-27 | Weiss Ervin I | Device, method and materials for mobilizing substances into dentinal tubules in root canal treatment |
DE10150121B4 (de) | 2001-10-11 | 2005-12-01 | Bernhard-Nocht-Institut für Tropenmedizin | Echtzeitdetektion von DNA-Amplifikationsprodukten |
US7297485B2 (en) | 2001-10-15 | 2007-11-20 | Qiagen Gmbh | Method for nucleic acid amplification that results in low amplification bias |
US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
US20040029129A1 (en) | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
DE10152821B4 (de) | 2001-10-25 | 2006-11-16 | Bruker Daltonik Gmbh | Massenspektren ohne elektronisches Rauschen |
EP1308506A1 (en) | 2001-11-06 | 2003-05-07 | Eidgenössische Technische Hochschule Zürich | Mixtures of Propionibacterium jensenii and Lactobacillus sp. with antimicrobial activities for use as a natural preservation system |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
BR0206488A (pt) | 2001-11-15 | 2008-08-05 | Whatman Inc | dispositivo, método e kit para armazenamento e análise de uma porção contendo ácido nucleico em uma amostra biológica |
US20040023209A1 (en) | 2001-11-28 | 2004-02-05 | Jon Jonasson | Method for identifying microorganisms based on sequencing gene fragments |
JP3692067B2 (ja) | 2001-11-30 | 2005-09-07 | 株式会社東芝 | 銅のcmp用研磨スラリーおよびそれを用いた半導体装置の製造方法 |
US20030148284A1 (en) | 2001-12-17 | 2003-08-07 | Vision Todd J. | Solid phase detection of nucleic acid molecules |
TW509116U (en) | 2001-12-18 | 2002-11-01 | Ind Tech Res Inst | Device for clipping and tightening spindle of honing and milling machine |
US20030175709A1 (en) | 2001-12-20 | 2003-09-18 | Murphy George L. | Method and system for depleting rRNA populations |
US7468185B2 (en) | 2001-12-21 | 2008-12-23 | Pfizer Inc. | Vaccine for periodontal disease |
KR100444230B1 (ko) | 2001-12-27 | 2004-08-16 | 삼성전기주식회사 | 내환원성 유전체 자기 조성물 |
AU2002358353A1 (en) | 2001-12-28 | 2003-07-30 | Keygene N.V. | Discrimination and detection of target nucleotide sequences using mass spectrometry |
EP1333101B1 (en) | 2002-02-01 | 2007-03-28 | Bruker Daltonik GmbH | Mutation analysis by PCR and Mass spectrometry |
CN1202204C (zh) | 2002-02-27 | 2005-05-18 | 财团法人工业技术研究院 | 红光有机电激发光化合物及用其制成的组件和装置 |
KR100600988B1 (ko) | 2002-03-13 | 2006-07-13 | 주식회사 엘지생명과학 | Dna 면역화에서 인플루엔자 np 유전자 dna를 함께투여하여 면역반응을 증가시키는 방법 |
US7024370B2 (en) | 2002-03-26 | 2006-04-04 | P) Cis, Inc. | Methods and apparatus for early detection of health-related events in a population |
US6897027B2 (en) | 2002-03-27 | 2005-05-24 | Decode Genetics Ehf. | Method for desalting nucleic acids |
WO2003100035A2 (en) | 2002-04-01 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Method for rapid detection and identification of viral bioagents |
US7539579B2 (en) | 2002-04-09 | 2009-05-26 | Beattie Kenneth L | Oligonucleotide probes for genosensor chips |
JP2004000200A (ja) | 2002-04-19 | 2004-01-08 | Menicon Co Ltd | 微生物の検出方法 |
FR2838740A1 (fr) | 2002-04-22 | 2003-10-24 | Centre Nat Rech Scient | Oligonucleotides issus des sequences codant pour la composante de surface des proteines d'enveloppe des ptlv et leurs utilisations |
GB0209812D0 (en) | 2002-04-30 | 2002-06-05 | Renovo Ltd | Genetic testing |
US6906319B2 (en) | 2002-05-17 | 2005-06-14 | Micromass Uk Limited | Mass spectrometer |
DE10222632B4 (de) | 2002-05-17 | 2006-03-09 | Con Cipio Gmbh | Mikrosatellitenmarker für genetische Analysen und zur Unterscheidung von Rosen |
EP1365031A1 (en) | 2002-05-21 | 2003-11-26 | MTM Laboratories AG | Method for detection of somatic mutations using mass spectometry |
US20030220844A1 (en) * | 2002-05-24 | 2003-11-27 | Marnellos Georgios E. | Method and system for purchasing genetic data |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
JP2005534292A (ja) | 2002-05-29 | 2005-11-17 | アレサ・バイオディテクション・アンパルトセルスカブ | 植物用レポーター系 |
GB0212666D0 (en) | 2002-05-31 | 2002-07-10 | Secr Defence | Immunogenic sequences |
AU2003238930A1 (en) | 2002-06-07 | 2003-12-22 | Incyte Corporation | Enzymes |
WO2003106635A2 (en) | 2002-06-13 | 2003-12-24 | Regulome Corp | Functional sites |
KR100484144B1 (ko) * | 2002-06-20 | 2005-04-18 | 삼성전자주식회사 | 원격 관리 서버 및 원격 관리 방법 |
CA2490283A1 (en) | 2002-07-01 | 2004-01-08 | Wayne State University | Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance |
WO2004009849A1 (en) | 2002-07-19 | 2004-01-29 | Isis Pharmaceuticals, Inc. | Methods for mass spectrometry analysis utilizing an integrated microfluidics sample platform |
US6916483B2 (en) * | 2002-07-22 | 2005-07-12 | Biodynamics, Llc | Bioabsorbable plugs containing drugs |
GB0217434D0 (en) | 2002-07-27 | 2002-09-04 | Royal Vetinary College | Biological material |
US20040022764A1 (en) | 2002-07-31 | 2004-02-05 | Hanan Polansky | Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease |
US7172868B2 (en) | 2002-08-01 | 2007-02-06 | The Regents Of The University Of California | Nucleotide sequences specific to Francisella tularensis and methods for the detection of Francisella tularensis |
US20040038385A1 (en) * | 2002-08-26 | 2004-02-26 | Langlois Richard G. | System for autonomous monitoring of bioagents |
CA2497988C (en) | 2002-09-06 | 2011-03-29 | The Trustees Of Boston University | Quantification of gene expression |
CA2410795A1 (en) | 2002-11-01 | 2004-05-01 | University Of Ottawa | A method for the amplification of multiple genetic targets |
WO2004044247A2 (en) | 2002-11-12 | 2004-05-27 | Genolife | One step real-time rt pcr kits for the universal detection of organisms in industrial products |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2004070001A2 (en) | 2002-11-15 | 2004-08-19 | Gen-Probe Incorporated | Assay and compositions for detection of bacillus anthracis nucleic acid |
US6680476B1 (en) | 2002-11-22 | 2004-01-20 | Agilent Technologies, Inc. | Summed time-of-flight mass spectrometry utilizing thresholding to reduce noise |
EP1578399A4 (en) | 2002-12-06 | 2007-11-28 | Isis Pharmaceuticals Inc | METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND BEETS |
JP2004201679A (ja) | 2002-12-10 | 2004-07-22 | Kao Corp | Pcr法によるフゾバクテリウム・ニュークレタム菌の検出用プライマー及びその検出方法 |
US20040117354A1 (en) | 2002-12-16 | 2004-06-17 | Azzaro Steven Hector | Process for tagging and measuring quality |
US20040121312A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of the absence of bioagents |
US20040122857A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby |
US20040121315A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby |
US20040121340A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent associated with host versus graft and graft versus host rejections thereby |
US20040121329A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in blood, bodily fluids, and bodily tissues thereby |
US20040122598A1 (en) | 2002-12-18 | 2004-06-24 | Ecker David J. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in food products and cosmetics thereby |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
JP2004201641A (ja) | 2002-12-26 | 2004-07-22 | Mitsubishi Kagaku Bio-Clinical Laboratories Inc | 真菌検出方法 |
US20040170954A1 (en) | 2003-02-10 | 2004-09-02 | Mckenney Keith | Pathogen inactivation assay |
US20040170981A1 (en) | 2003-02-10 | 2004-09-02 | Mckenney Keith | Real-time polymerase chain reaction using large target amplicons |
US20040185438A1 (en) | 2003-03-10 | 2004-09-23 | Ecker David J. | Methods of detection and notification of bioagent contamination |
US20050065813A1 (en) | 2003-03-11 | 2005-03-24 | Mishelevich David J. | Online medical evaluation system |
US8046171B2 (en) * | 2003-04-18 | 2011-10-25 | Ibis Biosciences, Inc. | Methods and apparatus for genetic evaluation |
US20050009053A1 (en) | 2003-04-25 | 2005-01-13 | Sebastian Boecker | Fragmentation-based methods and systems for de novo sequencing |
US8057993B2 (en) | 2003-04-26 | 2011-11-15 | Ibis Biosciences, Inc. | Methods for identification of coronaviruses |
WO2005009202A2 (en) | 2003-05-12 | 2005-02-03 | Isis Pharmaceuticals, Inc. | Automatic identification of bioagents |
US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
WO2005003384A1 (en) | 2003-07-03 | 2005-01-13 | Danmarks Og Grønlands Geologiske Undersøgelse | Method for selective detection of a target nucleic acid |
WO2005017173A1 (en) | 2003-07-29 | 2005-02-24 | Sigma Aldrich Co. | Methods and compositions for amplification of dna |
JP4304292B2 (ja) | 2003-07-30 | 2009-07-29 | 日本電気株式会社 | 移動通信システム、移動通信端末及びそれに用いるパワーコントロール方法並びにそのプログラム |
KR100632429B1 (ko) | 2003-08-01 | 2006-10-09 | 프로테온 주식회사 | 프라이머 특이성 유무에 의한 멀티플렉스 역전사 중합효소연쇄반응을 이용한 재조합 독감 바이러스의 스크리닝 방법 |
US20060240412A1 (en) | 2003-09-11 | 2006-10-26 | Hall Thomas A | Compositions for use in identification of adenoviruses |
US8242254B2 (en) | 2003-09-11 | 2012-08-14 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US20050142584A1 (en) | 2003-10-01 | 2005-06-30 | Willson Richard C. | Microbial identification based on the overall composition of characteristic oligonucleotides |
WO2005036369A2 (en) | 2003-10-09 | 2005-04-21 | Isis Pharmaceuticals, Inc. | Database for microbial investigations |
FR2861743B1 (fr) | 2003-11-04 | 2007-10-19 | Univ Aix Marseille Ii | Identification moleculaire des bacteries du genre corynebacterium |
US8163895B2 (en) | 2003-12-05 | 2012-04-24 | Ibis Biosciences, Inc. | Compositions for use in identification of orthopoxviruses |
US20050250125A1 (en) | 2003-12-19 | 2005-11-10 | Novakoff James L | Method for conducting pharmacogenomics-based studies |
ATE485401T1 (de) | 2004-02-10 | 2010-11-15 | Hoffmann La Roche | Neue primer und sonden zum nachweis von parvovirus b19 |
CA2560521C (en) | 2004-02-18 | 2012-01-03 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of bacteria |
US7666592B2 (en) | 2004-02-18 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US8119336B2 (en) | 2004-03-03 | 2012-02-21 | Ibis Biosciences, Inc. | Compositions for use in identification of alphaviruses |
US7312036B2 (en) | 2004-03-22 | 2007-12-25 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of viral hemorrhagic fever viruses |
US20050266411A1 (en) | 2004-05-25 | 2005-12-01 | Hofstadler Steven A | Methods for rapid forensic analysis of mitochondrial DNA |
US7627437B2 (en) | 2005-01-14 | 2009-12-01 | Idaho Research Foundation | Categorization of microbial communities |
DE102005008583B4 (de) | 2005-02-24 | 2007-10-25 | Johannes-Gutenberg-Universität Mainz | Verfahren zur Typisierung eines Individuums mittels short tandem repeat (STR)-Loci der genomischen DNA |
CA2600184A1 (en) | 2005-03-03 | 2006-09-08 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of adventitious viruses |
DE602006017365D1 (de) | 2005-04-13 | 2010-11-18 | Ibis Biosciences Inc | Zusammensetzungen für die identifizierung von adenoviren |
AU2006272776B2 (en) | 2005-07-21 | 2012-01-19 | Ibis Biosciences, Inc. | Methods for rapid identification and quantitation of nucleic acid variants |
US20070026435A1 (en) | 2005-07-28 | 2007-02-01 | Polysciences, Inc. | Hydroxysilane functionalized magnetic particles and nucleic acid separation method |
EP2126132B1 (en) | 2007-02-23 | 2013-03-20 | Ibis Biosciences, Inc. | Methods for rapid foresnsic dna analysis |
US20100204266A1 (en) | 2007-03-23 | 2010-08-12 | Ibis Biosciences, INC | Compositions for use in identification of mixed populations of bioagents |
-
2002
- 2002-12-18 US US10/326,051 patent/US20040121313A1/en not_active Abandoned
- 2002-12-18 US US10/323,233 patent/US20040121309A1/en not_active Abandoned
- 2002-12-18 US US10/325,527 patent/US20040121335A1/en not_active Abandoned
- 2002-12-18 US US10/325,526 patent/US20040121311A1/en not_active Abandoned
-
2003
- 2003-09-11 US US10/660,122 patent/US7781162B2/en not_active Expired - Fee Related
- 2003-12-05 CA CA002508584A patent/CA2508584A1/en not_active Abandoned
- 2003-12-05 JP JP2005508488A patent/JP2006508696A/ja active Pending
- 2003-12-05 WO PCT/US2003/038830 patent/WO2004052175A2/en active Search and Examination
- 2003-12-05 EP EP03796752A patent/EP1581657A4/en not_active Withdrawn
-
2007
- 2007-10-09 US US11/869,449 patent/US20080311558A1/en not_active Abandoned
- 2007-10-30 US US11/929,910 patent/US8214154B2/en not_active Expired - Fee Related
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830653A (en) * | 1991-11-26 | 1998-11-03 | Gilead Sciences, Inc. | Methods of using oligomers containing modified pyrimidines |
US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5645985A (en) * | 1991-11-26 | 1997-07-08 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5691141A (en) * | 1993-01-07 | 1997-11-25 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5622824A (en) * | 1993-03-19 | 1997-04-22 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US5872003A (en) * | 1993-03-19 | 1999-02-16 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US5763588A (en) * | 1993-09-17 | 1998-06-09 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5502177A (en) * | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US6005096A (en) * | 1993-09-17 | 1999-12-21 | Gilead Sciences, Inc. | Pyrimidine derivatives |
US5849492A (en) * | 1994-02-28 | 1998-12-15 | Phylogenetix Laboratories, Inc. | Method for rapid identification of prokaryotic and eukaryotic organisms |
US6268144B1 (en) * | 1995-03-17 | 2001-07-31 | Sequenom, Inc. | DNA diagnostics based on mass spectrometry |
US5965363A (en) * | 1996-09-19 | 1999-10-12 | Genetrace Systems Inc. | Methods of preparing nucleic acids for mass spectrometric analysis |
US6028183A (en) * | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
US6007992A (en) * | 1997-11-10 | 1999-12-28 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017322B2 (en) | 2001-03-02 | 2011-09-13 | Ibis Biosciences, Inc. | Method for rapid detection and identification of bioagents |
US9416424B2 (en) | 2001-03-02 | 2016-08-16 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8214154B2 (en) | 2001-03-02 | 2012-07-03 | Ibis Biosciences, Inc. | Systems for rapid identification of pathogens in humans and animals |
US8815513B2 (en) | 2001-03-02 | 2014-08-26 | Ibis Biosciences, Inc. | Method for rapid detection and identification of bioagents in epidemiological and forensic investigations |
US8265878B2 (en) | 2001-03-02 | 2012-09-11 | Ibis Bioscience, Inc. | Method for rapid detection and identification of bioagents |
US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US20040219517A1 (en) * | 2001-03-02 | 2004-11-04 | Ecker David J. | Methods for rapid identification of pathogens in humans and animals |
US8802372B2 (en) | 2001-03-02 | 2014-08-12 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US7718354B2 (en) | 2001-03-02 | 2010-05-18 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US7741036B2 (en) | 2001-03-02 | 2010-06-22 | Ibis Biosciences, Inc. | Method for rapid detection and identification of bioagents |
US7781162B2 (en) | 2001-03-02 | 2010-08-24 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US9752184B2 (en) | 2001-03-02 | 2017-09-05 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US8017743B2 (en) | 2001-03-02 | 2011-09-13 | Ibis Bioscience, Inc. | Method for rapid detection and identification of bioagents |
US8563250B2 (en) | 2001-03-02 | 2013-10-22 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
US8017358B2 (en) | 2001-03-02 | 2011-09-13 | Ibis Biosciences, Inc. | Method for rapid detection and identification of bioagents |
US8268565B2 (en) | 2001-03-02 | 2012-09-18 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
US10801074B2 (en) | 2001-06-04 | 2020-10-13 | Geneohm Sciences Canada, Inc. | Method for the detection and identification of methicillin-resistant Staphylococcus aureus |
US9777335B2 (en) | 2001-06-04 | 2017-10-03 | Geneohm Sciences Canada Inc. | Method for the detection and identification of methicillin-resistant Staphylococcus aureus |
US10577664B2 (en) | 2001-06-04 | 2020-03-03 | Geneohm Sciences Canada, Inc. | Method for the detection and identification of methicillin-resistant Staphylococcus aureus |
US20110238316A1 (en) * | 2001-06-26 | 2011-09-29 | Ecker David J | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8921047B2 (en) | 2001-06-26 | 2014-12-30 | Ibis Biosciences, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8298760B2 (en) | 2001-06-26 | 2012-10-30 | Ibis Bioscience, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8073627B2 (en) | 2001-06-26 | 2011-12-06 | Ibis Biosciences, Inc. | System for indentification of pathogens |
US8380442B2 (en) | 2001-06-26 | 2013-02-19 | Ibis Bioscience, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US9725771B2 (en) | 2002-12-06 | 2017-08-08 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8822156B2 (en) | 2002-12-06 | 2014-09-02 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8071309B2 (en) | 2002-12-06 | 2011-12-06 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8046171B2 (en) | 2003-04-18 | 2011-10-25 | Ibis Biosciences, Inc. | Methods and apparatus for genetic evaluation |
US8057993B2 (en) | 2003-04-26 | 2011-11-15 | Ibis Biosciences, Inc. | Methods for identification of coronaviruses |
US8476415B2 (en) | 2003-05-13 | 2013-07-02 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US7956175B2 (en) | 2003-09-11 | 2011-06-07 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US8013142B2 (en) | 2003-09-11 | 2011-09-06 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US8163895B2 (en) | 2003-12-05 | 2012-04-24 | Ibis Biosciences, Inc. | Compositions for use in identification of orthopoxviruses |
US8187814B2 (en) | 2004-02-18 | 2012-05-29 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US7666592B2 (en) | 2004-02-18 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US9447462B2 (en) | 2004-02-18 | 2016-09-20 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US8119336B2 (en) | 2004-03-03 | 2012-02-21 | Ibis Biosciences, Inc. | Compositions for use in identification of alphaviruses |
US9449802B2 (en) | 2004-05-24 | 2016-09-20 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US7714275B2 (en) | 2004-05-24 | 2010-05-11 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US8173957B2 (en) | 2004-05-24 | 2012-05-08 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US8987660B2 (en) | 2004-05-24 | 2015-03-24 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US20050270191A1 (en) * | 2004-05-24 | 2005-12-08 | Isis Pharmaceuticals, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US8407010B2 (en) | 2004-05-25 | 2013-03-26 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA |
US7811753B2 (en) | 2004-07-14 | 2010-10-12 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
US9873906B2 (en) | 2004-07-14 | 2018-01-23 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
US8182992B2 (en) | 2005-03-03 | 2012-05-22 | Ibis Biosciences, Inc. | Compositions for use in identification of adventitious viruses |
US8084207B2 (en) | 2005-03-03 | 2011-12-27 | Ibis Bioscience, Inc. | Compositions for use in identification of papillomavirus |
US8551738B2 (en) | 2005-07-21 | 2013-10-08 | Ibis Biosciences, Inc. | Systems and methods for rapid identification of nucleic acid variants |
US8026084B2 (en) | 2005-07-21 | 2011-09-27 | Ibis Biosciences, Inc. | Methods for rapid identification and quantitation of nucleic acid variants |
US20070111234A1 (en) * | 2005-09-12 | 2007-05-17 | Christian Birkner | Detection of biological DNA |
US11834720B2 (en) | 2005-10-11 | 2023-12-05 | Geneohm Sciences, Inc. | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx |
US20080227087A1 (en) * | 2005-10-11 | 2008-09-18 | Ann Huletsky | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx |
US9149473B2 (en) | 2006-09-14 | 2015-10-06 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
US8871471B2 (en) | 2007-02-23 | 2014-10-28 | Ibis Biosciences, Inc. | Methods for rapid forensic DNA analysis |
US10584392B2 (en) | 2007-06-01 | 2020-03-10 | Council Of Scientific And Industrial Research | Method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
US20090263809A1 (en) * | 2008-03-20 | 2009-10-22 | Zygem Corporation Limited | Methods for Identification of Bioagents |
US9027730B2 (en) | 2008-09-16 | 2015-05-12 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
US8534447B2 (en) | 2008-09-16 | 2013-09-17 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
US9023655B2 (en) | 2008-09-16 | 2015-05-05 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8148163B2 (en) | 2008-09-16 | 2012-04-03 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8550694B2 (en) | 2008-09-16 | 2013-10-08 | Ibis Biosciences, Inc. | Mixing cartridges, mixing stations, and related kits, systems, and methods |
US8609430B2 (en) | 2008-09-16 | 2013-12-17 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8252599B2 (en) | 2008-09-16 | 2012-08-28 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8158936B2 (en) | 2009-02-12 | 2012-04-17 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US9165740B2 (en) | 2009-02-12 | 2015-10-20 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US8796617B2 (en) | 2009-02-12 | 2014-08-05 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US9393564B2 (en) | 2009-03-30 | 2016-07-19 | Ibis Biosciences, Inc. | Bioagent detection systems, devices, and methods |
US8950604B2 (en) | 2009-07-17 | 2015-02-10 | Ibis Biosciences, Inc. | Lift and mount apparatus |
US9194877B2 (en) | 2009-07-17 | 2015-11-24 | Ibis Biosciences, Inc. | Systems for bioagent indentification |
US10119164B2 (en) | 2009-07-31 | 2018-11-06 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
US9416409B2 (en) | 2009-07-31 | 2016-08-16 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
EP2957641A1 (en) | 2009-10-15 | 2015-12-23 | Ibis Biosciences, Inc. | Multiple displacement amplification |
EP3225695A1 (en) | 2009-10-15 | 2017-10-04 | Ibis Biosciences, Inc. | Multiple displacement amplification |
US9890408B2 (en) | 2009-10-15 | 2018-02-13 | Ibis Biosciences, Inc. | Multiple displacement amplification |
WO2011047307A1 (en) | 2009-10-15 | 2011-04-21 | Ibis Biosciences, Inc. | Multiple displacement amplification |
WO2011112718A1 (en) | 2010-03-10 | 2011-09-15 | Ibis Biosciences, Inc. | Production of single-stranded circular nucleic acid |
US9752173B2 (en) | 2010-04-08 | 2017-09-05 | Ibis Biosciences, Inc. | Compositions and methods for inhibiting terminal transferase activity |
US9068017B2 (en) | 2010-04-08 | 2015-06-30 | Ibis Biosciences, Inc. | Compositions and methods for inhibiting terminal transferase activity |
EP3170831A1 (en) | 2011-09-06 | 2017-05-24 | Ibis Biosciences, Inc. | Sample preparation methods |
WO2013036603A1 (en) | 2011-09-06 | 2013-03-14 | Ibis Biosciences, Inc. | Sample preparation methods |
US10662485B2 (en) | 2011-12-27 | 2020-05-26 | Ibis Biosciences, Inc. | Bioagent detection oligonucleotides |
US9970061B2 (en) | 2011-12-27 | 2018-05-15 | Ibis Biosciences, Inc. | Bioagent detection oligonucleotides |
WO2014052590A1 (en) | 2012-09-26 | 2014-04-03 | Ibis Biosciences, Inc. | Swab interface for a microfluidic device |
Also Published As
Publication number | Publication date |
---|---|
CA2508584A1 (en) | 2004-06-24 |
WO2004052175A2 (en) | 2004-06-24 |
EP1581657A2 (en) | 2005-10-05 |
US20040121313A1 (en) | 2004-06-24 |
EP1581657A4 (en) | 2007-09-12 |
WO2004052175A3 (en) | 2004-11-11 |
US20040121311A1 (en) | 2004-06-24 |
US20040121335A1 (en) | 2004-06-24 |
US8214154B2 (en) | 2012-07-03 |
US20080311558A1 (en) | 2008-12-18 |
JP2006508696A (ja) | 2006-03-16 |
US20040219517A1 (en) | 2004-11-04 |
US7781162B2 (en) | 2010-08-24 |
US20120142085A1 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040121309A1 (en) | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues | |
US20040121314A1 (en) | Methods for rapid detection and identification of bioagents in containers | |
US20040121310A1 (en) | Methods for rapid detection and identification of bioagents in forensic studies | |
US20030190605A1 (en) | Methods for rapid detection and identification of bioagents for environmental testing | |
US20040121312A1 (en) | Methods for rapid detection and identification of the absence of bioagents | |
US20040122857A1 (en) | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby | |
US20030225529A1 (en) | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent for environmental testing thereby | |
US20040121315A1 (en) | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby | |
US20040122598A1 (en) | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in food products and cosmetics thereby | |
US20040121329A1 (en) | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in blood, bodily fluids, and bodily tissues thereby | |
US20040121340A1 (en) | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent associated with host versus graft and graft versus host rejections thereby | |
AU2002244250A1 (en) | Method for rapid detection and identification of bioagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ISIS PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ECKER, DAVID J.;GRIFFEY, RICHARD H.;SAMPATH, RANGARAJAN;AND OTHERS;REEL/FRAME:013881/0585;SIGNING DATES FROM 20030212 TO 20030218 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |
|
AS | Assignment |
Owner name: IBIS BIOSCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ISIS PHARMACEUTICALS, INC.;REEL/FRAME:019691/0584 Effective date: 20070814 Owner name: IBIS BIOSCIENCES, INC.,CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ISIS PHARMACEUTICALS, INC.;REEL/FRAME:019691/0584 Effective date: 20070814 |